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 ABSTRACT 
The objectives of the study was to determine the folate status 
in patient with chronic disease in Khartoum, Sudan and to correlate 
this alteration with disease pattern or mechanisms.They will get 
benefits from folate suplementaion as recomended. 
This is a prospective case control study conducted at the Police 
Teaching Hospital and Abuanjja Chest hospital from March 2005 to 
February 2006 
In this study 20 patients suffering from pulmonary 
tuberculosis, 20 patients with reuhmatoid arthritis,and 5 healthy 
controls were studied. Special selection criteria were considered for 
the patients as diagnosed with clinical history, examinations, and 
laboratory methods for conformation of diagnosis 
The study concluded that inspite of existance of anemia of 
chronic disease in 42.5%; only 2.5% (one patient) had a low serum 
folate, and 2 2. 5% (9 patients) with borderline serum folate. 
The study recommended that a large prospective study is 
needed to give a better idea of folate status in chronic disease, and  
that red cell folate is to be estimated as it is a better parameter of folate 
status than serum folate. It was also recommended  to do serum 
ferritin and homocystine  to know they are deficient & if so, the effect 
of that on the haematological state of these patients .  
  
 
It is recommended to given folate supplements to correct the 
anaemia in these patients & this will help improve their well being, 
keeping in mind that the drugs used in these diseases can cause folate 
deficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ﺺ اﻻﻃﺮوﺣﻪﻠﺨﺴﺘﻣ
ﻤﺭﻀﻰ ﺍﻟﺴل ﺍﻟﺭﺌﻭﻯ ﻭ ﺍﻟﺘﻬﺎﺏ  ﻟﻨﻘﺹ ﻓﻰ ﻓﻴﺘﺎﻤﻴﻥ ﺍﻟﺤﻤﺽ ﺍﻟﻔﻭﻟﻰ ﻓﻰﻫﺩﻓﺕ ﺍﻟﺩﺭﺍﺴﻪ ﻟﻤﻌﺭﻓﻪ ﺍ
  .ﺍﻟﺴﻭﺩﺍﻥ ﻭ ﻓﻰ ﺍﻟﺨﺭﻁﻭﻡ ﻭ ﺭﺒﻁﻪ ﻟﻠﻤﺘﻐﻴﺭﺍﺕ ﺍﻟﺘﻰ ﺘﺤﺩﺙ ﺍﺜﻨﺎﺀ ﺍﻟﻤﺭﺽل ﺍﻟﺭﺜﻭﺍﻨﻰ ﻓﻰ ﺍﻟﻤﻔﺎﺼ
 ﺍﻟﺘﻬﺎﺏ ﺍﻟﻤﻔﺎﺼل ﻫﺫﻩ ﺩﺭﺍﺴﺔ ﻤﻘﺎﺭﻨﺔ ﺘﺤﻠﻴﻠﻴﻪ ﺍﺠﺭﻴﺕ ﻓﻰ ﻤﺴﺘﺸﻔﻰ ﺍﻟﺸﺭﻁﻪ ﺍﻟﺘﻌﻠﻴﻤﻰ ﻗﺴﻡ
  .6002 ﺍﻟﻰ ﻓﺒﺭﺍﻴﺭ 5002ﻤﺭﺍﺽ ﺍﻟﺼﺩﺭ ﻓﻰ ﺍﻟﻔﺘﺭﺓ ﻤﺎ ﺒﻴﻥ ﻤﺎﺭﺱ ﻷﺒﻭ ﻋﻨﺠﻪ ﺃ ﻭﻤﺴﺘﺸﻔﻰ ﺍﻟﺭﺜﻭﺍﻨﻰ
 ، ﺍﻟﺘﻬﺎﺏ ﺍﻟﻤﻔﺎﺼل ﺍﻟﺭﺜﻭﺍﻨﻰﻴﻌﺎﻨﻭﻥ ﻤﻥ ﻤﻨﻬﻡ  02 ﺤﺎﻟﻪ ﻤﺭﻀﻴﻪ54ﺎﺭ ﺨﺘﻴﺇﻓﻰ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ ﺘﻡ 
  .ﺸﺨﺎﺹ ﻻ ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﺍﻯ ﻤﺭﺽ ﺃ 5ﻴﻀﺎ ﺃﻭ ، ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﻤﺭﺽ ﺍﻟﺴل ﺍﻟﺭﺌﻭﻯ02ﻭ
 ﻴﻜﻭﻥ ﺍﻟﻤﺭﻴﺽ ﻟﺩﻴﻪ ﺸﻜﻭﻯ ﻟﻤﺩﻩ  ﺃﻥﻋﺘﺒﺎﺭﻹﺨﺫﻴﻥ ﻓﻰ ﺍﺁﺨﺘﻴﺎﺭ ﺍﻟﻤﺭﻀﻰ ﻹﺘﻡ  ﻭﻀﻊ ﺍﺴﺱ 
  .ﻨﻪ ﺘﻡ ﺘﺸﺨﻴﺼﻪ ﻤﻌﻤﻠﻴﺎﺃ ﻭﻴﺔﻥ ﺘﻅﻬﺭ ﺒﻪ ﻋﻼﻤﺎﺕ ﺴﺭﻴﺭﺃﻭ .ﻁﻭﻴﻠﻪ
ﺸﺨﺹ )% 5.2 ﺍﻟﻰ ﺍﻥ ﻨﺴﺒﺔ ﺍﻟﻨﻘﺹ ﻓﻰ ﺍﻟﺤﻤﺽ ﺍﻟﻔﻭﻟﻰ ﺘﻤﺜﻠﺕ ﻓﻰ ﻨﺴﺒﻪ ﺨﻠﺼﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ
   (ﺘﺴﻊ ﺍﺸﺨﺎﺹ% )5.22ﻭ ﺘﺤﺕ ﺍﻟﻤﻌﺩل ﺍﻟﻁﺒﻴﻌﻰ ،( ﻭﺍﺤﺩ
ﻔﻴﻀﻪ ﻟﺩﺭﺍﺴﻪ ﻨﻘﺹ ﺍﻟﺤﻤﺽ ﺘﻓﻰ ﻨﻬﺎﻴﻪ ﺍﻟﻤﻁﺎﻑ ﺍﻭﺼﺕ ﺍﻟﺩﺭﺍﺴﻪ ﺒﺎﺠﺭﺍﺀ ﺩﺭﺍﺴﻪ ﺍﺨﺭﻯ ﻤﺴ
ﺭﻭﺭﺓ ﺘﺤﻠﻴل ﻨﻘﺹ ﺍﻟﺤﻤﺽ ﻭﺼﺕ ﺒﻀ ﻜﻤﺎ ﺃ،ﺍﻟﺴل ﺍﻟﺭﺌﻭﻯ ﻭ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻤﻔﺎﺼل ﺍﻟﺭﺜﻭﺍﻨﻰﺍﻟﻔﻭﻟﻰ ﻓﻰ 
 ﻓﻰ ﺍﻟﺤﻤﺽ ﺍﻟﻔﻭﻟﻰ ﺩﻗﺔ ﻓﻲ ﺍﻟﻜﺸﻑ ﻋﻥ ﻜﻤﻴﺔ ﻤﺨﺯﻭﻥ ﺍﻟﻔﻭﻟﻰ ﻓﻰ ﺨﻼﻴﺎ ﺍﻟﺩﻡ ﺍﻟﺤﻤﺭﺍﺀ ﻻﻨﻬﺎ ﺍﻜﺜﺭ
ﻭﺼﺕ ﺒﻀﺭﻭﺭﺓ ﻗﻴﺎﺱ ﻨﻘﺹ ﺍﻟﺤﺩﻴﺩ ﺍﻟﻤﺼﺎﺤﺏ ﻟﻪ ﻭ ﻗﻴﺎﺱ ﺍﻟﺤﻤﺽ ﺍﻻﻤﻴﻨﻰ ﻜﺫﻟﻙ ﺃ. ﺍﻟﺠﺴﻡ
ﻥ ﺃﻻﻨﻪ ﻤﻌﺭﻭﻑ ،ﺫ ﺍﺜﺒﺕ ﺫﻟﻙ  ﺇﻘﺹﻭﻜﺫﻟﻙ ﺍﻋﻁﺎﺀ ﺍﻟﺤﻤﺽ ﺍﻟﻔﻭﻟﻰ ﻓﻰ ﺤﺎﻟﻪ ﺍﻟﻨ. ﺍﻟﻬﻭﻤﻭﺴﺴﺘﻴﻥ
 ﺘﺘﺴﺒﺏ ﻓﻰ (ﺍﻟﺴل ﺍﻟﺭﺌﻭﻯ ﻭ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻤﻔﺎﺼل ﺍﻟﺭﺜﻭﺍﻨﻰ)ﻤﺭﺍﺽ ﻷﺩﻭﻴﻪ ﺍﻟﻤﺴﺘﺨﺩﻤﻪ ﻓﻰ ﻋﻼﺝ ﻫﺫﻩ ﺍﻷﺍ
  .  ﻨﻘﺹ ﺍﻟﺤﻤﺽ ﺍﻟﻔﻭﻟﻰ
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 1. INTRODUCTION & LITRETURE REVIEW 
 
1.1. Anaemia:  
Background:  
Anemia is strictly defined as a decrease in red blood cell (RBC) 
mass. Methods for measuring RBC mass are time consuming, are 
expensive, and usually require transfusion of radio labeled 
erythrocytes. Thus, in practice, anemia is usually discovered and 
quantified by measurement of the RBC count, hemoglobin (Hb) 
concentration, and hematocrit (Hct). These values should be 
interpreted cautiously because they are concentrations affected by 
changes in plasma volume. For example, dehydration elevates these 
values, and increased plasma volume in pregnancy can diminish them 
without affecting the RBC mass. 
Pathophysiology:  
Erythroid precursors develop in bone marrow at rates usually 
determined by the requirement for sufficient circulating Hb to 
oxygenate tissues adequately. Erythroid precursors differentiate 
sequentially from stem cells to progenitor cells to erythroblasts to 
normoblasts in a process requiring growth factors and cytokines. This 
process of differentiation requires several days. Normally, erythroid 
precursors are released into circulation as reticulocytes.  
 Reticulocytes remain in the circulation for approximately 1 day 
before reticulin is excised by reticuloendothelial cells with the 
delivery of the mature erythrocyte into circulation. The mature 
erythrocyte remains in circulation for about 120 days before being 
engulfed and destroyed by phagocytic cells of the reticuloendothelial 
system.(1) 
Erythrocytes are highly deformable and increase their 
diameter from 7 µm to 13 µm when they traverse capillaries with a 
3µm diameter. They possess a negative charge on their surface, which 
may serve to discourage phagocytosis. Because erythrocytes have no 
nucleus, they lack a Krebs cycle and rely on glycolysis via the 
Embden-Meyerhof and pentose pathways for energy. Many enzymes 
required by the aerobic and anaerobic glycolytic pathways decrease 
within the cell as it ages. In addition, the aging cell has a decrease in 
potassium concentration and an increase in sodium concentration. 
These factors contribute to the demise of the erythrocyte at the end of 
its 120-day lifespan.  
RBCs contain fluid Hb encased in a lipid membrane supported 
by a cytoskeleton. Abnormalities of the membrane, the chemical 
composition of the Hb, or certain glycolytic enzymes can reduce the 
lifespan of RBCs to cause anemia. Basically, only 3 causes of anemia 
exist: blood loss, increased RBC destruction (hemolysis), and 
decreased production of RBCs. Each of these 3 causes includes a 
number of etiologies that require specific and appropriate therapy. 
 Often, the etiology can be determined if the RBCs are altered in either 
size or shape or if they contain certain inclusion bodies. For example, 
Plasmodium falciparum malaria is suggested by the presence of more 
than one ring form in an RBC and produces pan-hemolysis of RBCs of 
all ages.(1) 
1.1.1. Frequency: 
In the US: The prevalence of anemia in population studies of 
healthy nonpregnant people depends on the Hb concentration chosen 
for the lower limit of normal values. The World Health Organization 
chose 12.5 g/dL for both adult males and females. In the United 
States, limits of 13.5 g/dL for men and 12.5 g/dL for women are 
probably more realistic. Using these values, approximately 4% of men 
and 8% of women have values lower than those cited. A significantly 
greater prevalence is observed in patient populations. Less 
information is available regarding studies using RBC or Hct. 
Internationally: The prevalence of anemia in Canada and 
northern Europe is believed to be similar to that in the United States. 
In underprivileged countries, limited studies of purportedly healthy 
subjects show the prevalence of anemia to be 2-5 times greater than 
that in the United States. Although geographic diseases, such as sickle 
cell anemia, thalassemia, malaria, hookworm, and chronic infections, 
are responsible for a portion of the increase, nutritional factors with 
iron deficiency and, to a lesser extent, folic acid deficiency play major 
 roles in the increased prevalence of anemia. Populations with little 
meat in the diet have a high incidence of iron deficiency anemia 
because heme iron is better absorbed from food than inorganic iron.  
 
 
1.1.2. Mortality/Morbidity:  
The morbidity and mortality of anemias vary greatly 
depending on the etiology. Acute hemorrhage has variable mortality 
depending on the site of bleeding (80% with aortic rupture, 30-50% 
with bleeding esophageal varices, approximately 1% with benign 
peptic ulcers). Anemia from gastrointestinal bleeding may be the first 
evidence of an intestinal malignancy. Sickle cell disease may be 
associated with frequent painful crises and a shortened lifespan, or 
patients with sickle cell disease may remain relatively asymptomatic 
with a nearly normal lifespan. Most patients with beta-0 homozygous 
thalassemia die during the second or third decade of life unless they 
undergo bone marrow transplantation. Hereditary spherocytosis 
either may present with a severe hemolytic anemia or may be 
asymptomatic with compensated hemolysis. Similarly, glucose-6-
phosphate dehydrogenase (G-6-PD) deficiency may manifest as 
chronic hemolytic anemia or exist without anemia until the patient 
receives an oxidant medication. The 2-year fatality rate for severe 
 aplastic anemia is 70% without bone marrow transplantation or a 
response to immunosuppressive therapy.  
Many symptoms associated with anemia are not caused by 
diminished RBC mass. Patients with pernicious anemia are often 
asymptomatic when they are detected incidentally with an Hb of            
6 g/dL. In contrast, ice chewing, calf cramps, and diminished 
capability to perform muscular work occur in iron deficiency anemia 
with an Hb of 10-11 g/dL because of depletion of iron-containing 
proteins other than Hb.  
In addition, tolerance of anemia is proportional to the anemia's 
rate of development. Symptoms and mortality associated with rapidly 
developing anemia are more profound than in slowly developing 
anemia. 
• Race: Certain races and ethnic groups have an increased prevalence 
of genetic factors associated with certain anemias. Examples are 
hemoglobinopathies, thalassemia, and G-6-PD deficiency. Each of 
these disorders has different morbidity and mortality in different 
populations due to differences in the genetic abnormality producing 
the disorder. For example, G-6-PD deficiency and thalassemia have 
less morbidity in African Americans than in Sicilians because of 
differences in the genetic fault. Conversely, sickle cell anemia has a 
greater morbidity and mortality in African Americans than among 
Saudi Arabians. Socioeconomic advantages are more prevalent 
among white individuals than individuals of other races. This affects 
 diet and the availability of health care and leads to a decreased 
prevalence of nutritional anemias and anemia associated with 
chronic untreated illnesses.  
•  Sex: Overall, anemia is twice more prevalent in females than in 
males. This difference is significantly greater during the childbearing 
years due to pregnancies and menses. Approximately 65% of body 
iron is incorporated into circulating Hb. Each gram of Hb contains 
3.46 mg of iron (1 mL of blood with Hb of 15 g/dL = 0.5 mg of iron). 
Each healthy pregnancy depletes the mother of approximately 500 
mg of iron. While a man must absorb about 1 mg of iron to maintain 
equilibrium, a premenopausal woman must absorb an average of       
2 mg daily. Further, because women eat less food than men, they 
must be more than twice as efficient as men in the absorption of 
sufficient iron to avoid iron deficiency. Women have a markedly 
lower incidence of anemia from X-linked anemias, such as G-6-PD 
deficiency and sex-linked sideroblastic anemias.(2) 
•  Age: Severe genetically acquired anemias (e.g., sickle cell disease, 
thalassemia, Fanconi syndrome) are more commonly found in 
children because they do not survive to adulthood. During the 
childbearing years, women are more likely to become iron deficient. 
Neoplasia increases in prevalence with each decade of life and can 
produce anemia from bleeding, from the replacement of bone 
marrow with tumor, or from the development of anemia associated 
with chronic disorders. Use of aspirin, nonsteroidal anti-
 inflammatory drugs (NSAIDs), and Coumadin increases with age 
and can produce gastrointestinal bleeding. 
•  History: Carefully obtain a history and perform a physical 
examination in every patient with anemia because the findings 
usually provide important clues to the etiology of the underlying 
disorder. From the standpoint of the investigation of the anemia, 
asking questions in addition to those conventionally explored 
during a routine examination is important. Areas of inquiry found 
valuable are briefly described below. Often, the duration of anemia 
can be established by obtaining a history of previous blood 
examination and, if necessary, by acquiring those records. Similarly, 
a history of rejection as a blood donor or prior prescription of 
hematinics provides clues that anemia was detected previously. 
Obtain a careful family history not only for anemia but also for 
jaundice, cholelithiasis, splenectomy, bleeding disorders, and 
abnormal Hbs. Carefully document the patient's occupation, 
hobbies, prior medical treatment, drugs (including over-the-counter 
medications and vitamins), and household exposures to potentially 
noxious agents. Patients are unlikely to volunteer exposures to 
tranquilizers, insecticides, paints, solvents, and hair dyes unless 
specifically queried. In searching for blood loss, carefully document 
pregnancies, abortions, and menstrual loss. Estimates of menstrual 
losses are notoriously inaccurate if only routine inquiry is made. 
Often, patients do not appreciate the significance of tarry stools. 
 Changes in bowel habits can be useful in uncovering neoplasms of 
the colon. Hemorrhoidal blood loss is difficult to quantify, and it 
may be overlooked or overestimated from one patient to another. 
Obviously, seek a careful history of gastrointestinal complaints that 
may suggest gastritis, peptic ulcers, hiatal hernias, or diverticula. 
Abnormal urine color can occur in renal and hepatic disease and in 
hemolytic anemia. A thorough dietary history is important in a 
patient who is anemic. This history must include foods that the 
patient both eats and avoids as well as an estimate of their quantity. 
A meal-by-meal description is necessary to obtain appropriate 
339estimates. Even then, patients frequently attempt to deceive the 
physician because of embarrassment regarding dietary 
idiosyncrasies or financial restrictions. In these circumstances, a 
close and concerned family member participating in the dietary 
history can often be helpful because this person is usually more 
objective than the patient. 
Specifically question patients regarding consumption of either 
clay or laundry starch. This history will not be provided 
spontaneously. These substances render iron less absorbable.  
Changes in body weight are important with regard to dietary 
intake and can suggest the presence of malabsorption or an 
underlying wasting disease of infectious, metabolic, or neoplastic 
origin. 
 Nutritional deficiencies may be associated with unusual 
symptoms that can be elicited by a history. 
Patients with iron deficiencies frequently chew or suck ice 
(pagophagia). Occasionally, they complain of dysphasia, brittle 
fingernails, relative impotence, fatigue, and cramps in the calves on 
climbing stairs that are out of proportion to their anemia. 
In vitamin B-12 deficiency, early graying of the hair, a burning 
sensation of the tongue, and a loss of proprioception are common.  
Suspect a loss of proprioception if the patient stumbles in the 
dark or must look in order to put on pants in the morning.  
Paresthesia or unusual sensations frequently described as pain 
also occur in pernicious anemia.  
Patients with folate deficiencies may have a sore tongue, 
cheilosis, and symptoms associated with steatorrhea. 
Color, bulk, frequency, and odor of stools and whether the 
feces float or sink can be helpful in detecting malabsorption. More 
sensitive questions to detect steatorrhea include whether the toilet 
needs to be flushed more than once to rid it of stool and whether an 
oily substance is floating on the water surface after the first flush. 
Obtain a history or the presence of fever because infections, 
neoplasms, and collagen vascular disease can cause anemia. Similarly, 
the occurrence of purpura, ecchymoses, and petechiae suggest the 
 occurrence of either thrombocytopenia or other bleeding disorders; 
this may be an indication either that more than one bone marrow 
lineage is involved or that coagulopathy is a cause of the anemia 
because of bleeding. 
Cold intolerance can be an important symptom of 
hypothyroidism or lupus erythematosus, paroxysmal cold 
hemoglobinuria, and certain macroglobulinemias. 
The relation of dark urine to either physical activity or time of 
day can be important in March hemoglobinuria and paroxysmal 
nocturnal hemoglobinuria. 
Explore the presence or the absence of symptoms suggesting 
an underlying disease, such as cardiac, hepatic, and renal disease; 
chronic infection; endocrinopathy; or malignancy. 
Physical: Too often, the physician rushes into the physical 
examination without looking at the patient for an unusual habitus or 
appearance of underdevelopment, malnutrition, or chronic illness. 
These findings can be important clues to the underlying etiology of 
disease and provide information related to the duration of illness. The 
skin and mucous membranes are often bypassed so that pallor, 
abnormal pigmentation, icterus, spider nevi, petechiae, purpura, 
angiomas, ulcerations, palmar erythema, coarseness of hair, puffiness 
of the face, thinning of the lateral aspects of the eyebrows, nail defects, 
 and a usually prominent venous pattern on the abdominal wall are 
missed in the rush to examine the heart and the lungs. 
Examine optic fundi carefully but not at the expense of the 
conjunctivae and the sclerae, which can show pallor, icterus, splinter 
hemorrhages, petechiae, and comma signs in the conjunctival vessels, 
or telangiectasia that can be helpful in planning additional studies. 
Perform systematic examination for palpable enlargement of 
lymph nodes for evidence of infection or neoplasia. Bilateral edema is 
useful in disclosing underlying cardiac, renal, or hepatic disease, 
whereas unilateral edema may portend lymphatic obstruction due to 
a malignancy that cannot be observed or palpated. 
Carefully search for both hepatomegaly and splenomegaly. 
Their presence or absence is important, as are the size, the tenderness, 
the firmness, and the presence or the absence of nodules. In patients 
with chronic disorders, these organs are firm, nontender, and 
nonnodular. In patients with carcinoma, they may be hard and 
nodular. The patient with an acute infection usually has a palpably 
softer and more tender organ. 
A rectal and pelvic examination cannot be neglected because 
tumor or infection of these organs can be the cause of anemia. 
The neurologic examination should include tests of position 
sense and vibratory sense, examination of the cranial nerves, and 
testing for tendon reflexes. The heart should not be ignored because 
 enlargement may provide evidence of the duration and the severity of 
the anemia, and murmurs may be the first evidence of a bacterial 
endocarditis that could explain the etiology of the anemia. 
Causes: Causes of anemia are numerous and multifaceted. A 
family history may be useful in detecting hereditary etiology. Diet 
and exposure to drugs and chemicals can be useful. A geographic 
history and a thorough knowledge of the patient's health can be 
important in establishing an etiology.  
- Genetic. 
- Hemoglobinopathies. 
- Thalassemias. 
- Enzyme abnormalities of the glycolytic pathways. 
- Defects of the RBC cytoskeleton. 
- Congenital dyserythropoietic anemia. 
- Rh null disease.     
- Hereditary xerocytosis. 
- Abetalipoproteinemia.  
- Fanconi anemia. 
- Nutritional. 
- Iron deficiency.  
 - Vitamin B-12 deficiency. 
- Folate deficiency.  
- Starvation and generalized malnutrition. 
- Hemorrhage.  
- Immunologic - Antibody-mediated abnormalities. 
- Physical effects. 
- Trauma.  
- Burns.  
- Frostbite. 
- Prosthetic valves and surfaces. 
- Drugs and chemicals. 
- Aplastic anemia. 
- Megaloblastic anemia. 
- Chronic diseases and malignancies. 
- Renal disease. 
- Hepatic disease. 
- Chronic infections. 
- Neoplasia.  
 - Collagen vascular diseases. 
- Infections. 
- Viral - Hepatitis, infectious mononucleosis, cytomegalovirus. 
- Bacterial - Clostridia, gram-negative sepsis. 
- Protozoal - Malaria, leishmaniasis, toxoplasmosis. 
- Thrombotic thrombocytopenic purpura and hemolytic uremic 
syndrome. 
1.1.3. Lab studies: 
The first step in the diagnosis of anemia is detection with 
reliable accurate tests so that important clues to underlying disease 
are not overlooked and patients are not subjected to unnecessary tests 
for and treatment of nonexistent anemia. Detection of anemia involves 
the adoption of arbitrary criteria. 
 The World Health Organization's criterion for anemia in 
adults is Hb values less than 12.5 g/dL. Children aged 6 months to 6 
years are considered anemic at Hb levels less than 11 g/dL, and 
children aged 6-14 years are considered anemic when Hb levels are 
less than 12 g/dL. The disadvantage of such arbitrary criteria is that a 
few healthy individuals fall below the reference range, and some 
people with an underlying disorder fall within the reference range for 
Hb concentration.  
 Usually, US values are slightly higher. Anemia is suggested in 
males with Hb levels less than 13.5 g/dL and in females with Hb 
levels less than 12.5 g/dL. Higher values are anticipated in 
individuals living in altitudes significantly above sea level. Conditions 
with an increase in plasma volume, such as during the last trimester 
of pregnancy, are associated with lower values without an existent 
anemia because the red cell mass is normal. 
Once the existence of anemia is established, investigate the 
pathogenesis. If an adequate history has been taken and a physical 
examination has been performed, the etiology may be obvious and 
confirmatory studies and appropriate therapy can be undertaken with 
a minimum of investigation. If this is not the case, initiate a definite 
plan of investigation considering the cost to the patient along with a 
determination of the etiology of the abnormality. 
A rational approach is to begin by examining the peripheral 
smear and laboratory values obtained on the blood count. If the 
anemia is either microcytic (mean corpuscular volume [MCV], <84) or 
macrocytic (MCV, >96) or if certain abnormal RBCs or WBCs are 
observed in the blood smear, the investigative approach can be 
limited (see Tables 1, and  2). 
Presently, RBC cellular indices are computer calculated and 
automatically placed on laboratory reports. The formulae for 
calculating these values follow (reference ranges are in parentheses). 
RBC is per million cells. 
 MCV = Hct × 10/RBC (84-96 fL) 
Mean corpuscular Hb (MCH) = Hb × 10/RBC (26-36 pg) 
Mean corpuscular Hb concentration (MCHC) = Hb × 10/Hct (32-36%)  
A rapid method of determining whether cellular indices are 
normocytic and normochromic is to multiply the RBC and Hb by 3. 
The RBC multiplied by 3 should equal the Hb, and the Hb multiplied 
by 3 should equal the Hct. Deviation from the calculated values 
suggests microcytosis, macrocytosis, or hypochromia versus the 
presence of spherocytes (MCHC, >36).  
 
Table 1: Macrocytic Anemia (MCV, >95) 
Deficiency of vitamin B-12 
Deficiency of folic acid 
Drugs affecting DNA synthesis 
 
Megaloblastic bone marrow 
Inherited disorders of DNA synthesis 
Liver disease Nonmegaloblastic bone marrow 
Hypothyroidism and hypopituitarism 
 Accelerated erythropoiesis (reticulocytes) 
Hypoplastic and aplastic anemia 
Infiltrated bone marrow 
Table 2: Various Forms of RBCs 
Macrocyte Larger than normal (>8.5 m diameter). See Table 1. 
Microcyte Smaller than normal (<7 m diameter).  
Hypochromic Less hemoglobin in cell. Enlarged area of central pallor.  
Spherocyte Loss of central pallor, stains more densely, often microcytic. 
Hereditary spherocytosis and certain acquired hemolytic anemias. 
Target cell Hypochromic with central "target" of hemoglobin. Liver disease, 
thalassemia, hemoglobin D, postsplenectomy. 
Leptocyte Hypochromic cell with a normal diameter and decreased MCV. 
Thalassemia. 
Elliptocyte Oval to cigar shaped. Hereditary elliptocytosis, certain anemias 
(particularly vitamin B-12 and folate deficiency). 
Schistocyte Fragmented helmet- or triangular-shaped RBCs. Microangiopathic 
anemia, artificial heart values, uremia, malignant hypertension. 
 Stomatocyte Slitlike area of central pallor in erythrocyte. Liver disease, acute 
alcoholism, malignancies, hereditary stomatocytosis, and artifact. 
Tear-shaped 
RBCs 
Drop-shaped erythrocyte, often microcytic. Myelofibrosis and 
infiltration of marrow with tumor. Thalassemia. 
Acanthocyte Five to 10 spicules of various lengths and at irregular interval on 
surface of RBCs. 
Echinocyte Evenly distributed spicules on surface of RBCs, usually 10-30. 
Uremia, peptic ulcer, gastric carcinoma, pyruvic kinase deficiency, 
preparative artifact. 
Sickle cell Elongated cell with pointed ends. Hemoglobin S and certain types of 
hemoglobin C and l. 
 
 
 
 
In microcytic hypochromic anemia, seek a source of bleeding. 
The appropriate laboratory tests are serum iron level and TIBC and 
either serum ferritin level or stain of bone marrow specimen for iron. 
If the serum iron level is decreased and TIBC is increased, a diagnosis 
of iron deficiency can be made, therapy can be initiated, and a search 
for the cause of the iron deficiency can be started. If this cannot be 
 demonstrated, suspect each of the other causes of a microcytic 
anemia, and the order of investigation can be influenced by findings 
in the history, physical examination, or peripheral smear.  
Similarly, a reasonable approach with macrocytic anemia is to 
determine if the bone marrow aspirate is megaloblastic. If so, attempt 
to incriminate either vitamin B-12 or folic acid deficiency with 
appropriate laboratory studies. Similar to the establishment of a 
diagnosis of iron deficiency anemia, a diagnosis of vitamin B-12 or 
folic acid deficiency does not stop with an abnormal laboratory value 
for one of these vitamins. Prompt treatment can be instituted, but a 
continued search for an underlying cause of the vitamin deficiency is 
indicated (see pernicious anemia). 
When a normocytic normochromic anemia is encountered, 
classify the anemia into 3 possible etiologies (ie, blood loss, hemolysis, 
decreased production). In most anemias, one of these causes is the 
dominant factor. However, in certain anemias, more than a single 
cause may play an important role. For example, pernicious anemia is 
predominantly due to decreased production of erythrocytes, but 
hemolysis adds significantly to the severity of anemia.(3,4) 
1.1.4 Blood loss: 
Obviously, significant hemorrhage produces anemia. 
Immediately after blood loss, the Hct cannot be used as a reliable 
method to determine the quantity of lost blood because the patient 
 loses plasma as well as RBCs. After acute hemorrhage, the Hct falls 
for 24-48 hours until the plasma volume is replaced. At that time, 
anemia is normochromic and normocytic with normal cellular indices 
because the cells in the peripheral blood have been produced prior to 
bleeding (see Iron Deficiency Anemia).  
If the patient had adequate iron stores, accelerated production 
of RBCs occurs, so that 1 week after bleeding, a larger than normal 
number of young RBCs and reticulocytes are circulating in the 
peripheral blood. Because reticulocytes and young RBCs have a larger 
volume (MCV of approximately 120), macrocytes may be observed in 
the peripheral smear, and a slight increase in the MCV occurs. 
If hemorrhage was sufficient to deplete iron stores (1-2 L of 
blood, 500-1000 mg of iron), newly formed erythrocytes are microcytic 
and hypochromic and gradually replace normal erythrocytes in the 
circulation that were produced prior to the induction of iron 
deficiency. Because RBCs normally survive for 120 days in circulation, 
maximal changes in the MCV and MCHC are not observed until that 
time. Iron deficiency and the depletion of iron stores can be detected 
several weeks after bleeding by measurements of the serum iron level 
and TIBC and/or special stains of bone marrow specimens showing 
an absence of storage iron.  
Diagnosis of iron deficiency anemia in an adult in the United 
States should be attributed to bleeding unless other causes can be 
proven. Aside from recent multiparity, other causes are relatively 
 uncommon and include prolonged dietary idiosyncrasies (e.g., clay 
eating, laundry starch consumption, protein deprivation for several 
years), urinary loss of iron due to intravascular hemolysis (e.g., 
artificial aortic valves, paroxysmal nocturnal hemoglobinuria), 
gastrectomy, and other upper gastrointestinal surgery or disease. 
Diagnosis of iron deficiency anemia is made by demonstrating that 
the patient has low serum iron levels and elevated TIBC, absence of 
stainable iron in a bone marrow specimen, or both. A low serum 
ferritin level provides confirmation of the diagnosis. The presence of 
microcytosis and hypochromia is helpful but not diagnostic.  
Microcytic hypochromic anemia is observed with conditions 
other than iron deficiency anemia. Certain types of these disorders are 
iron-overloading states in which the administration of iron can be 
deleterious to the patient. Similarly, low serum iron levels can be 
observed in chronic inflammatory states with normal body stores of 
iron. However, in the latter, the TIBC is usually decreased rather than 
increased, and stainable iron can be demonstrated in bone marrow 
aspirates. Whenever the diagnosis of iron deficiency anemia is in 
doubt, follow-up blood work after administration of iron to show 
correction of the anemia can be helpful in confirming the diagnosis.  
The patient notices hemorrhage from most body organs. 
Epistaxis, hemoptysis, or hematuria of sufficient degree to cause 
anemia is usually reported to the physician long before iron 
deficiency ensues. However, bleeding from either the uterus or the 
 gastrointestinal tract may be disregarded by the patient or be totally 
undetected until anemia becomes profound and symptomatic. 
Menstrual bleeding among healthy females varies monthly 
from 10- 250 mL. Unless the patient observes a change in menses, she 
relates that menses are normal unless specific questions are asked. 
The presence of clots, abdominal cramps, excessive gushing of blood 
upon removal of tampons, the need for both tampons and pads, and 
the use of an unusual number of pads or tampons can be used to 
determine if menstrual bleeding may be sufficient to induce iron 
deficiency anemia.  
Gastrointestinal bleeding is the other occult cause of anemia 
due to blood loss. If hemorrhage is profuse, it is usually detected 
before evidence of iron deficiency anemia occurs because 
hematochezia or melena causes the patient to seek medical attention. 
However, if the bleeding occurs slowly, it is usually undetected until 
anemia ensues because stools appear normal.  
Every patient with iron deficiency anemia should have a stool 
examination for occult blood. A positive result necessitates a careful 
search of the gastrointestinal tract to identify the site of bleeding. 
Unfortunately, a negative result does not exclude gastrointestinal 
blood loss because bleeding can be intermittent and require several 
examinations for detection. Also, less than 20-30 mL of blood in the 
stool per day may go undetected due to the insensitivity of the test. 
The 2 methods used to detect small daily losses of blood from the gut 
 are as follows: (1) placing the patient on a meat-free diet for several 
days and using more sensitive methods, such as a benzidine test, and 
(2) labeling the patient's RBCs with chromium 51 and collecting stool 
specimens for the detection of the radioisotope. Investigate 
gastrointestinal bleeding by endoscopy and radiographic studies. 
1.1.5. Hemolysis (increased RBC destruction): 
A normal RBC survives in the circulation for 120 days. If the 
erythrocytic lifespan is shortened significantly (<40 d), the patient has 
a hemolytic disorder that may be demonstrated by showing increased 
production of erythrocytes, increased destruction, or both. The former 
is revealed most readily by the presence of sustained reticulocytosis 
and the latter by the occurrence of indirect bilirubinemia (Table 3).  
Other laboratory tests are available to detect hemolysis, but 
they are either more expensive or less reliable. 
 
Table 3: Classification of the Hemolytic Disorders 
 Hereditary Acquired
Intracorpuscular defect Hereditary spherocytosis
Hereditary elliptocytosis
Hemoglobinopathies
Thalassemias
Congenital dyserythropoietic anemias
Hereditary RBC enzymes 
 
  
 
1.1.6. Anemia of chronic disease (ACD) - definition 
ACD is a common type of anemia that occurs in patients with 
infectious, inflammatory, or neoplastic diseases that persist for more 
than 1 or 2 months. It does not include anemias caused by marrow 
replacement, blood loss, hemolysis, renal insufficiency, hepatic 
disease, or endocrinopathy, even when these disorders are chronic. 
The ACD is extremely common. ACD is more common that any 
anemia syndrome other than blood loss with consequent iron 
deficiency. ACD is the most common cause of anemia in hospitalized 
patients. After patients with bleeding, hemolysis, or known 
hematologic malignancy were excluded, 52% of anemic patients met 
laboratory criteria for the anemia of chronic disorders. ACD is 
observed in 27% of outpatients with rheumatoid arthritis and in 58% 
of new admissions to hospital rheumatology units.(1) 
 
1.1.7 Disorders associated with the anemia of chronic disease: 
         Chronic infections: 
- Pulmonary infections: abscesses, emphysema, tuberculosis,             
and pneumonia.  
- Subacute bacterial endocarditis.  
 - Pelvic inflammatory disease. 
- Chronic urinary tract infections. 
- Chronic fungal disease. 
- HIVinfections. 
- Osteomyelitis. 
Chronic, noninfectious inflammations: 
 - Rheumatoid arthritis. 
 - Systemic lupus erythematosus (SLE). 
 - Sever trauma, thermal injury. 
 - Vasculitis. 
Malignant diseases: 
 - Cancer. 
 - Hodgkin’s disease and Non-Hodgkin’s Lympmhomas. 
 - Leukemias. 
 - Multiple myeloma 
Miscellanous:  
 - Alcoholic liver disease. 
 - Thrombophlebitis. 
  - Ischemic heart disease. 
-  Idiopathic.  
1.1.7.1. Pathogenesis: 
- Shortened red cell life span, moderately 20-30% (from 120 to 60-90 
days).   
- Relative bone marrow(erythropoiesis) failure. 
- Cytokines released from inflammatory cells (TNF-α,  IL-1, IFN-γ) 
affects erythropoiesis by inhibiting the growth of  erythroid 
progenitors. 
-  Serum erythropoietin levels in patiens with ACD are normal when 
compared to healthy subjects but much lower than levels in non-
ACD anemic patients. 
Abnormal iron metabolism: 
Activation of the reticuloendothelial system with increased 
iron retention and storage within it impaired release of iron from 
macrophages to circulating transferrin (impaired reutilization of iron). 
Reduced concentration of transferrin(decreased production, 
increase sequestration in the spleen and in the foci of inflammation, 
increase loss). 
1.1.7.2. Symptoms: 
 Symptoms of the underlying disease (malignancy or chronic 
inflammatory disease) 
Symptoms of the anemia: 
Laboratory features: 
• The anemia is usually mild or moderate (Hb 7-11g/dl): lower values 
are observed in 20-30% of patients. 
•  The anemia is  most often normochromic and normocytic (MCHC 
and MCV are normal) 
 - MCV 70-80 fl in 5-40% of patients with ACD.  
 - MCHC  26-32 g/dl in 40-70%. 
• Erythrocyte  sedimentation rate (ESR) - usually rapid 
• Retikulocytes - most often normal or slightly decreased number, 
increased count is rarely  
• Iron metabolism: 
 1. Serum Iron - decreased (it is necessary for the diagnosis of ACD) 
 2. TIBC - reduced or low-normal. 
3. Transferrin saturation (TS) - moderately decreased (higher than in 
iron-deficiency anemia), usually > 10% 
 4. Serum Ferritin-increased or normal.  
  5. Serum Transferrin Receptor (sTR) Normal. 
 6. Sideroblasts in the bone marrow-reduced (5-20%). 
Laboratory Iron deficiency ACD: 
Features                                    without iron                with iron  
                                        deficiency                  deficiency            
sFe                           ↓ ↓                       ↓                              ↓ 
 
TS                        ↓<10%               ↓>10%                    ↓<10% 
 
TIBC                        ↑                       ↓, N        N, ↓ 
 
sFerritin           ↓<10µg/L         ↑>200µg/L, N        ↓<30µg/L, N               
  
Sideroblasts           <10%                10-20%                   <10% 
 
sTR                            ↑                         N                            ↑ 
Adventages of ACD for patients: 
 • Withdrawal of iron by increased storage of the metal within the 
reticuloendothelial system acts to limit the availability of iron to 
microorganisms or tumor cells and thereby inhibit their growth 
and proliferation. 
• Decreased hemoglobin reduces the oxygen transport capacity of 
the blood and decreases the overall oxygen supply, which may 
primarily affect rapid proliferating (malignant) tissues and micro-
organism. 
• Retention and storage of iron in retucoendothelial system directly 
and indirectly via cytokines strongly affects cell mediated immune 
function. 
Therapy: 
1. Treatment of the underlying disorder 
2. Iron supplementation (IS) 
- For patients with ACD with chronic infection or malignancy IS 
should be strictly avoided 
- IS benefit patients with ACD associated with auto-immune or 
rheumatic disorders.  
- When ACD is complicated by iron deficiency (about 27% 
patients) 
 3. Transfusion demands (about 30%) patients who have low Hb and 
are symptomatic. 
4. Recombinant erythropoietin 10.000 units 3 times a week i.v. or s.c.  
2-3 g, in the absence of response 20000 units, if there is still no 
respose, the treatment should be discontinued (in 40% of patients it 
reduces number of transfusions). 
5. Sequential administration of erythropoietin and iron (48 hours later). 
6. Iron chelation with deferoxamine - in some patients’ therapy was 
associated with a rise in hemoglobin level 
7. In future anti-TNF-antibodies. 
I have done my research in two type of disease Rheumatoid 
arthritis (chronic inflammatory) and Tuberculosis (chronic infection) 2 
 
1.2. Rheumatoid arthritis (RA): 
Background: Rheumatoid arthritis (RA) is a chronic systemic 
inflammatory disease of undetermined etiology involving primarily 
the synovial membranes and articular structures of multiple joints. 
The disease is often progressive and results in pain, stiffness, and 
swelling of joints. In late stages deformity and ankylosis develop.  
Pathophysiology: The cause of RA is unknown. The diagnosis 
is based routinely on the persistence of arthritic symptoms over time. 
 The application of classification systems based on qualifying 
symptom criteria or on decision-tree methodology also aids in 
establishing a diagnosis. 
Factors associated with RA include the possibility of infectious 
triggers, genetic predisposition, and autoimmune response. CD4+ T 
cells stimulate the immune cascade leading to cytokine production 
such as tumor necrosis factor alpha (TNF-α) and interleukin-1.  
The primary targets of inflammation are synovial membranes 
and articular structures. Other organs are affected as well. 
Inflammation, proliferation, and degeneration typify synovial 
membrane involvement. Joint deformities and disability result from 
the erosion and destruction of synovial membranes and articular 
surfaces. The disease course may be short and limited or progressive 
and severe.(4) 
Frequency: 
• In the US: Prevalence is approximately 1% in the United States. The 
occurrence rate ranges from 0.5% to greater than 5% depending on 
ethnic variation. 
• Internationally: Prevalence is similar to that in the United States.  
• Mortality/Morbidity: Mortality from RA is related primarily to the 
patient's overall deterioration in health, well-being, and 
functionality. Patients with RA become susceptible to infection and 
 secondary organ dysfunction (eg, lung disease, kidney disease, GI 
hemorrhage).  
•  Sex: Female-to-male ratio is approximately 3:1.  
•  Age: Age of onset is usually between 25 and 50 years. The disease 
can occur at any age but tends to peak in the fourth and fifth 
decades of life. The pediatric form of RA is juvenile rheumatoid 
arthritis (JRA), which is characterized by onset in children younger 
than 16 years and includes 3 categories of disease: polyarticular (ie, 
multiple joints affected), pauciarticular (ie, fewer than 4 joints 
affected), and systemic (ie, high fever, rash, organ involvement).  
•  History: RA is usually a disease of insidious onset, although it can 
be abrupt. The diagnosis typically is made when 4 of 7 qualifying 
criteria established by the American Rheumatism Association are 
met. These qualifying criteria are as follows: 
- Morning stiffness lasting longer than 1 hour before improvement 
Arthritis involving 3 or more joints. 
- Arthritis of the hand, particularly involvement of the proximal 
interphalangeal (PIP) joints, metacarpophalangeal (MCP) joints, or 
wrist joints. 
-  Bilateral involvement of joint areas (ie, both wrists, symmetric PIP 
and MCP joints). 
- Positive serum rheumatoid factor (RF). 
 -  Rheumatoid nodules. 
- Radiographic evidence of RA. 
• Other contributing history includes general malaise, weakness, fever 
of undetermined etiology, weight loss, myalgias, tendonitis and 
bursitis.  
• Physical: Joint involvement is typically polyarticular and 
symmetrical, usually sparing the distal interphalangeal (DIP) joints. 
Joint involvement and inflammation is evinced by oedema, effusion, 
warmth, tenderness to palpation, and destruction (a late finding). 
Subcutaneous rheumatoid nodules, swan-neck deformities, 
boutonniere deformities, ulnar deviation of fingers at MCP joints 
(late findings).  
• Bursitis: Various inflammatory disorders of remote organ systems 
may be present and may contribute to the presenting problem. 
Organ systems that may be affected include cardiac, carditis, 
pericarditis, pulmonary, pleuritis, intrapulmonary nodules, and 
interstitial fibrosis, hepatic – hepatitis, ocular - Scleritis, episcleritis, 
dryness of the eyes, vascular–vasculitis, skin-subcutaneous nodules, 
ulcers.  
• RA is a diffuse systemic disease involving many areas of the body. 
The presenting complaint may be remote from a joint or may 
involve inflammatory symptoms at a joint. 
 • Causes: The cause of RA has not been elucidated. Several possible 
associations have been described. 
• Associated factors may include the following genetic predisposition, 
female sex, psychological stress, immune response, hormone 
interaction, viral infection.  
Lab Studies:  
Complete blood count (CBC) indicates the presence of anemia 
in approximately 80% of patients with RA. The anemia is normocytic 
and normochromic. Thrombocytosis may be present. 
Erythrocyte sedimentation rate (ESR) is elevated in 
approximately 90% of patients with RA. This test usually is not 
performed in the acute setting. 
Serum RF result is positive in approximately 70% of patients 
with RA. This test is not performed in the ED. 
Antinuclear antibodies (ANA) are present in approximately 
30% of patients with RA. This test is not performed in the ED. 
 
 
 
Imaging Studies:  
 Radiography: 
Joints: Typical findings occur later in the disease course and 
include bony erosions, cysts, osteopenia, joint space swelling, 
calcifications, narrowed joint space, deformities, separations, and 
fractures. Cervical spine: RA can affect the cervical spine with 
inflammation and destruction of cartilage, bone, and ligaments. This 
most commonly occurs in the upper cervical spine. Laxity and 
destruction of ligaments can lead to significant instability with frank 
subluxation and cord damage. 
CT and/or MRI of joints and cervical spine: 
CT and/or MRI can delineate further the pathology described 
above. MRI may be necessary to demonstrate cord compression. 
Other Tests:  
Joint fluid analysis: 
Joint fluid analysis usually reveals a WBC count of 2,000-
50,000/mm3 and no crystals or bacteria.This may not be the case if 
gout, pseudogout, or infection is present. 
Procedures: 
Joint space aspiration 
 Consider joint space aspiration when making the definitive 
diagnosis of RA or when ruling out coexistent infection or crystal 
arthritis in an acutely swollen joint.  
Analyze fluid for Gram stain, cell count, culture, and overall 
appearance.Glucose and protein analyses are of limited value. 
Emergency Department Care:  
Many nonmedication therapies are available for RA, including 
exercise, diet, massage, counseling, stress reduction, physical therapy, 
and surgery. Medication-based therapies comprise several classes of 
drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), 
disease-modifying anti-rheumatologic drugs (DMARDs, also known 
as slow-acting antirheumatic drugs or SAARDS), 
immunosuppressants, biologic response modifiers, and 
corticosteroids. Although ED presentations may be due to initial 
disease presentation, patients with RA more commonly present with 
exacerbations of known disease or manifestations in other organ 
systems or sequelae. The following represent possible presentations:  
Patients presenting with initial presentation of previously 
undiagnosed possible RA require symptomatic treatment with NSAID 
therapy and rapid referral for definitive diagnosis and institution of 
DMARD therapy. Delay of as little as 2-3 months in initiating joint 
sparing therapy results in significant irreversible joint damage 
measured radiographically at 5 years.(4) 
 In patients with known disease, increased pain, edema, and 
dysfunction are characteristics of rheumatoid flare (exacerbation). 
Flares may be local or systemic in nature. Laboratory evaluation may 
reveal elevation in acute phase reactants. Treatment consists of rest, 
NSAIDs, DMARDs, short courses of steroids (2-4 wk), and possibly 
intraarticular steroid injections. Pain relief is important and may 
necessitate short-term use of narcotic analgesics. 
Felty syndrome is a triad of RA, neutropenia, and 
splenomegaly. Patients with Felty syndrome are prone to serious 
bacterial infections that result in higher rates of morbidity and 
mortality than for other patients with RA. This requires prompt 
diagnosis and initiation of antibiotic therapy. 
Ruptured Baker cysts are often confused with deep vein 
thrombosis (DVT). Baker cysts often occur fairly early in the course of 
the disease, with pain, edema, and inflammation in the posterior knee 
and calf. The diagnosis is best made with ultrasonography. Treatment 
includes rest, elevation, and needle puncture of the calf, knee joint 
aspiration, and referral. 
Carpal tunnel syndrome (median nerve compression 
neuropathy) is evinced by pain and/or paresthesias in the median 
nerve distribution of the hand, a positive Phalen and/or positive Tinel 
test, or positive electromyography. Therapy includes rest, temporary 
immobilization, NSAIDs, and surgery. 
 Cervical spine instability may be observed in patients with 
established RA who have degeneration of the ligaments and bone in 
the C-spine area. Degeneration of the transverse ligament can lead to 
instability at the C1-C2 level. Minor trauma can lead to neurologic 
sequelae due to inherent instability. Exercise caution when evaluating 
patients with RA after minor falls, motor vehicle accidents (MVAs), or 
other injuries. Cervical spine injury may occur spontaneously. 
Keratoconjunctivitis sicca occurs in approximately 25% of 
patients with RA. Symptoms include ocular discharge, foreign body 
sensation, and dry eye. Episcleritis may progress to scleromalacia if 
untreated. Treatment includes referral to ophthalmology, artificial 
tears, systemic NSAIDs, topical NSAIDs, systemic steroids, and 
cyclophosphamide. 
Consultations: 
Consultation is necessary for this chronic disease. New onset 
disease requires rapid diagnosis and therapy with DMARDS. 
Rheumatoid flares and other sequelae require close follow up. 
Patients always should be referred back to their primary care 
physician/rheumatologist promptly for continuation of care. 
Consultation with rheumatology, orthopedics, and/or 
infectious disease may be necessary if indicated by the presenting 
complaint. Involvement by cardiology, pulmonology, nephrology, 
 and ophthalmology often is necessitated by secondary organ 
involvement in those areas. 
Treatment: 
The treatment of RA historically has been a stepwise, pyramid 
progression beginning with rest, salicylates, and NSAIDs and 
progressing to the use of disease-modifying medications. Current 
recommendations suggest that for all but minor disease, the use of 
DMARDs and biologic response modifiers or combination drug 
therapy earlier in the disease course is more effective. Destruction of 
synovial tissue and joints can occur early in the disease process, before 
patients classically have been considered for progression of therapy. 
Effective medications include methotrexate, sulfasalazine, 
corticosteroids, hydroxychloroquine, gold injections, d-penicillamine, 
minocycline, azathioprine, cyclosporine, etanercept, and leflunomide. 
The primary goals of ED management should be relief of acute 
symptomatology, ruling out significant complications, and 
coordination of chronic therapy with the patient's primary care 
physician and rheumatologist. 
Drug Category: NONSTEROIDAL ANTI-INFLAMMATORY 
DRUGS (NSAIDS) -NSAIDs have been the cornerstone of therapy for 
RA. NSAIDs reduce pain and inflammation and allow for 
improvements in mobility and function. Several NSAIDs exist, but no 
single agent is clearly superior to another. The cyclooxygenase-2 
 (COX-2) inhibitors may offer some increase in efficacy with fewer 
adverse GI effects. The use of NSAIDs alone as single agents in RA 
should be reserved for mild, well-controlled disease. COX-2 inhibitors 
may be more effective in controlling inflammation.  
Drug Category: CYCLOOXYGENASE-2 (COX-2) 
INHIBITORS.Although increased cost can be a negative factor, the 
incidence of costly and potentially fatal GI bleeds is clearly less with 
COX-2 inhibitors than with traditional NSAIDs. Ongoing analysis of 
cost avoidance of GI bleeds will further define the populations that 
will find COX-2 inhibitors the most beneficial. 
Drug Category: DISEASE-MODIFYING AGENTS. These 
drugs most frequently are used in various combination therapy 
regimens. They include methotrexate, hydroxychloroquine, gold, d-
penicillamine, sulfasalazine, cyclosporine A, minocycline, 
azathioprine, leflunomide, infliximab, and etanercept. Please note that 
in JRA, d-penicillamine, gold, and antimalarials have not been proven 
effective. Pediatric safety has not been established for some of the 
newer agents. 
Drug Category: INTERLEUKIN-1 RECEPTOR INHIBITORS. 
Block effects of interleukin-1, which, in turn, may reduce 
inflammation and pain. 
Drug Category: GLUCOCORTICOIDS. These agents, used 
alone or in conjunction with other medications, may reduce the 
 symptomatology associated with RA. These drugs can be given at low 
doses daily for maintenance or in large doses pulsed over 3 days for a 
rheumatoid flare. 
Prognosis:  
Prognosis in RA is extremely variable. Some evidence suggests 
that the onset of disease (rapid versus insidious) may predict the 
progression of disease. Patients with rapid onset of disease may show 
better remission than those with insidious onset. Prognosis is worse 
with large joint involvement. 
Patient education:  
Patients with RA require a great deal of education regarding 
the need for lifestyle changes to prevent exacerbations, to preserve 
mobility and functionality, and for appropriate pain management. 
Specific education for the ED visit is focused on the exacerbation or 
focal problem for which the patient presents.(3) 
 
1.3. Tuberculosis: 
Mycobacterium tuberculosis: 
Mycobacterium tuberculosis is the etiologic agent of 
tuberculosis in humans. Humans are the only reservoir for the 
bacterium.  
 Mycobacterium bovis is the etiologic agent of TB in cows and 
rarely in humans. Both cows and humans can serve as reservoirs. 
Humans can also be infected by the consumption of unpasteurized 
milk. This route of transmission can lead to the development of 
extrapulmonary TB, exemplified in history by bone infections that led 
to hunched backs. 
Other human pathogens belonging to the Mycobacterium 
genus include Mycobacterium avium which causes a TB-like disease 
especially prevalent in AIDS patients, and Mycobacterium leprae, the 
causative agent of leprosy.5  
History and Present Day Importance:  
Mycobacterium tuberculosis (M.TB.) was the cause of the 
"White Plague" of the 17th and 18th centuries in Europe. During this 
period nearly 100 percent of the European population was infected 
with M.TB. And 25 percent of all adult deaths were caused by M.TB. 
(Note: The White Plague is not to be confused with the "Black Plague", 
which was caused by Yesinia pestis and occurred about 3 centuries 
earlier). 
 
 
General Characteristics: 
 Mycobacterium tuberculosis is a fairly large nonmotile rod-
shaped bacterium distantly related to the Actinomycetes. Many non 
pathogenic mycobacteria are components of the normal flora of 
humans, found most often in dry and oily locales. The rods are 2-4 um 
in length and 0.2-0.5 um in width.  
Mycobacterium tuberculosis is an obligate aerobe. For this 
reason, in the classic case of tuberculosis, the M.TB complexes are 
always found in the well-aerated upper lobes of the lungs. The 
bacterium is a facultative intracellular parasite, usually of 
macrophages, and has a slow generation time, 15-20 hours, a 
physiological characteristic that may contribute to its virulence.  
Two media are used to grow M.TB. Middlebrook's medium 
which is an agar based medium and Lowenstein-Jensen medium 
which is an egg based medium. M.TB. colonies are small and buff 
colored when grown on either medium. Both types of media contain 
inhibitors to keep contaminants from out-growing M.TB. It takes 4-6 
weeks to get visual colonies on either type of media.  
Chains of cells in smears made from in vitro-grown colonies 
often form distinctive serpentine cords. This observation was first 
made by Robert Koch who associated cord factor with virulent strains 
of the bacterium.  
M.TB. is not classified as either Gram-positive or Gram-
negative because it does not have the chemical characteristics of 
 either, although the bacteria do contain peptidoglycan (murine) in 
their cell wall. If a Gram stain is performed on M.TB, it stains very 
weakly Gram-positive or not at all (referred to as "ghosts").  
Mycobacterium species, along with members of a related 
genus Nocardia, are classified as acid-fast bacteria due to their 
impermeability by certain dyes and stains. Despite this, once stained, 
acid-fast bacteria will retain dyes when heated and treated with 
acidified organic compounds. One acid-fast staining method for 
Mycobacterium tuberculosis is the Ziehl-Neelsen stain. When this 
method is used, the M.TB smear is fixed, stained with carbol-fuchsin 
(a pink dye), and decolorized with acid-alcohol. The smear is 
counterstained with methylene-blue or certain other dyes. Acid-fast 
bacilli appear pink in a contrasting background.  
In order to detect Mycobacterium tuberculosis in a sputum 
sample, in excess of 10,000 organisms per ml of sputum are needed to 
visualize the bacilli with a 100X microscope objective. One acid-fast 
bacillus/slide is regarded as "suspicious" of an M.TB infection.  
Cell wall structure: 
The cell wall structure of Mycobacterium tuberculosis deserves 
special attention because it is unique among prokaryotes and it is a 
major determinant of virulence for the bacterium. The cell wall 
complex contains peptidoglycan, but otherwise it is composed of 
 complex lipids. Over 60% of the mycobacterial cell wall is lipid. The 
lipid fraction of M.TB's cell wall consists of three major components.  
Mycolic acids are unique alpha-branched lipids found in cell 
walls of Mycobacterium and Corynebacterium. They make up 50% of 
the dry weight of the mycobacterial cell envelope.  Mycolic acids are 
strong hydrophobic molecules that form a lipid shell around the 
organism and affect permeability properties at the cell 
surface.  Mycolic Acids are are thought to be a significant determinant 
of virulence in M.TB. Probably, they prevent attack of the 
mycobacteria by cationic proteins, lysozyme and oxygen radicals in 
the phagocytic granule. They also protect extracellular mycobacteria 
from complement deposition in serum.  
Cord Factor is responsible for the serpentine cording 
mentioned above. Cord factor is toxic to mammalian cells and is also 
an inhibitor of PMN migration. Cord factor is most abundantly 
produced in virulent strains of M.TB.  
Wax-D in the cell envelope is the major component of Freund's 
complete adjuvant (CFA).  
In summary, the high concentration of lipids in the cell wall of 
Mycobacterium tuberculosis has been associated with these properties of 
the bacterium: 
• Impermeability to stains and dyes. 
 •  Resistance to many antibiotics. 
•  Resistance to killing by acidic and alkaline compounds. 
•  Resistance to osmotic lysis via complement deposition. 
•  Resistance to lethal oxidations and survival inside of 
macrophages. 
 
  
TB infection means that M.TB. Is in the body but the immune 
system is keeping the bacteria under control. The immune system 
does this by producing macrophages that surround the tubercle 
bacilli. The cells form a hard shell that keeps the bacilli contained and 
under control.  Most people with TB infection have a positive reaction 
to the tuberculin skin test.  People who have TB infection but not TB 
disease are NOT infectious, i.e., they cannot spread the infection to 
other people. These people usually have a normal chest x-ray. TB 
infection is not considered a case of TB. Major similarities and 
differences between TB infection and TB disease are shown below. 6 
 Predisposing factors for TB infection include:  
• Close contact with large populations of people, i.e., schools, nursing 
homes, dormitories, prisons, …etc. 
• Poor nutrition. 
 •  IV drug use 
•  Alcoholism. 
•  HIV infection is the nr 1 predisposing factor for M.TB infection.  
• 10 percent of all HIV-positive individuals harbor M.TB. This is 400-
times the rate associated with the general public. 
•  Only 3-4% of infected individuals will develop active disease upon 
initial infection, 5-10% within one year. These percentages are much 
higher if the individual is HIV+.  
 
 
 
Stages of the Disease: 
The following stages that will be explained are for a M.TB 
sensitive host. It should be realized that, as stated previously, only a 
small percent of M.TB infections progress to disease and even a 
smaller percent progress all the way to stage 5. Usually the host will 
control the infection at some point.  
Disease progression depends on:  
• Strain of M.TB. 
•  Prior exposure 
 •  Vaccination. 
•  Infectious dose.  
•  Immune status of the host.  
• Stage 1: Droplet nuclei are inhaled. One droplet nuclei contains no 
more than 3 bacilli. Droplet nuclei are so small that they can remain 
air-borne for extended periods of time. The most effective (infective) 
droplet nuclei tend to have a diameter of 5 um. Droplet nuclei are 
generated by during talking coughing and sneezing.  Coughing 
generates about 3000 droplet nuclei. Talking for 5 minutes generates 
3000 droplet nuclei but singing generates 3000 droplet nuclei in one 
minute.  Sneezing generates the most droplet nuclei by far, which 
can spread to individuals up to 10 feet away. Spread of droplet 
nuclei from one individual to another. After droplet nuclei are 
inhaled, the bacteria are nonspecifically taken up by alveolar 
macrophages. However, the macrophages are not activated and are 
unable to destroy the intracellular organisms. Tuberculosis begins 
when droplet nuclei reach the alveoli. When a person inhales air that 
contains droplets most of the larger droplets become lodged in the 
upper respiratory tract (the nose and throat), where infection is 
unlikely to develop. However, the smaller droplet nuclei may reach 
the small air sacs of the lung (the alveoli), where infection begins.  
•  Stage 2: Begins 7-21 days after initial infection. M.TB multiplies 
virtually unrestricted within inactivated macrophages until the 
 macrophages burst. Other macrophages begin to extravasate from 
peripheral blood. These macrophages also phagocytose M.TB, but 
they are also unactivated and hence can not destroy M.TB. 
•  Stage 3: At this stage lymphocytes begin to infiltrate. The 
lymphocytes, specifically T-cells, recognize processed and presented 
M.TB antigen in context of MHC molecules. This results in T-cell 
activation and the liberation of cytokines including gamma 
interferon (IFN). The liberation of IFN causes in the activation of 
macrophages. These activated macrophages are now capable of 
destroying M.TB. It is at this stage that the individual becomes 
tuberculin-positive. This positive tuberculin reaction is the result of 
the host developing a vigorous cell mediated immune (CMI) 
response. A CMI response must be mounted to control an M.TB 
infection. An antibody mediated immune (AMI) will not aid in the 
control of a M.TB infection because M.TB is intracellular and if 
extracellular, it is resistant to complement killing due to the high 
lipid concentration in its cell wall. Although a CMI response is 
necessary to control an M.TB infection, it is also responsible for 
much of the pathology associated with tuberculosis. Activated 
macrophages may release lytic enzymes and reactive intermediates 
that facilitate the development of immune pathology. Activated 
macrophages and T-cells also secrete cytokines that may also play a 
role in the development of immune pathology, including Interleukin 
1 (IL-l), tumor necrosis factor (TNF), and gamma IFN. It is also at 
 this stage that tubercle formation begins. The center of the tubercle 
is characterized by "caseation necrosis" meaning semi-solid or 
"cheesy" consistency. M.TB cannot multiply within these tubercles 
because of the low pH and anoxic environment. M.TB can, however, 
persist within these tubercles for extended periods.  
•  Stage 4: Although many activated macrophages can be found 
surrounding the tubercles, many other macrophages present remain 
inactivated or poorly activated. M.TB uses these macrophages to 
replicate and hence the tubercle grows. The growing tubercle may 
invade a bronchus. If this happens, M.TB infection can spread to 
other parts of the lung. Similarly the tubercle may invade an artery 
or other blood supply line. The hematogenous spread of M.TB may 
result in extrapulmonary tuberculosis otherwise known as milliary 
tuberculosis. The name "milliary" is derived from the fact that 
metastasizing tubercles are about the same size as a millet seed, a 
grain commonly grown in Africa. The secondary lesions caused by 
milliary TB can occur at almost any anatomical location, but usually 
involve the genitourinary system, bones, joints, lymph nodes, and 
peritoneum. These lesions are of two types:  
a. Exudative lesions result from the accumulation of PMN's around 
M.TB. Here the bacteria replicate with virtually no resistance. 
This situation gives rise to the formation of a "soft tubercle".  
 b. Productive or granulomatous lesions occur when the host 
becomes hypersensitive to tuberculoproteins. This situation gives 
rise to the formation of a "hard tubercle".  
• Stage 5: For unknown reasons, the caseous centers of the tubercles 
liquify. This liquid is very conducive to M.TB growth and hence the 
organism begins to rapidly multiply extracellularly. After time, the 
large antigen load causes the walls of nearby bronchi to become 
necrotic and rupture. This results in cavity formation. This also 
allows M.TB to spill into other airways and rapidly spread to other 
parts of the lung. As stated previously, only a very small percent of 
M.TB infections result in disease and even a smaller percentage of 
M.TB infections progress to an advanced stage. Usually the host will 
begin to control the infection at some point. When the primary lesion 
heals, it becomes fibrous and calcifies. When this happens the lesion 
is referred to as the Ghon complex. Depending on the size and 
severity, the Ghon complex may never subside. Typically the Ghon 
complex is readily visible upon chest X-ray. Small metastatic foci 
containing low numbers of M.TB may also calcify. However, in 
many cases these foci will contain viable organisms. These foci are 
referred to Simon foci. The Simon foci are also visible upon chest X-
ray and are often the site of disease reactivation.  
Virulence Mechanisms and Virulence Factors:  
 Mycobacterium tuberculosis does not possess the classic 
bacterial virulence factors such as toxins, capsules and fimbriae. 
However, a number of structural and physiological properties of the 
bacterium are beginning to be recognized for their contribution to 
bacterial virulence and the pathology of tuberculosis.  
M.TB. has special mechanisms for cell entry. The tubercle 
bacillus can bind directly to mannose receptors on macrophages via 
the cell wall- associated mannosylated glycolipid, LAM, or indirectly 
via certain complement receptors or Fc receptors.  
M.TB. can grow intracellularly, this is an effective means of 
evading the immune system. In particular, antibodies and 
complement are ineffective. Once M.TB is phagocytosed, it can inhibit 
phagosome-lysosome fusion. The exact mechanism used by M.TB to 
accomplish this is not known but it is thought to be the result of a 
protein secreted by bacterium that modifies the phagosome 
membrane. The bacterium may remain in the phagosome or escape 
from the phagosome, in either case finding a protected environment 
for growth in the macrophage.  
M.TB. interferes with the toxic effects of reactive oxygen 
intermediates produced in the process of phagocytosis by two 
mechanisms.  
Compounds including glycolipids, sulfatides and LAM down 
regulate the oxidative cytotoxic mechanism. Macrophage uptake via 
 complement receptors may bypass the activation of a respiratory 
burst.  
Antigen 85 complex: This complex is composed of a group of 
proteins secreted by M.TB those are known to bind fibronectin. These 
proteins may aid in walling off the bacteria from the immune system 
and may facilitate tubercle formation although evidence of this is 
lacking.  
Slow generation time: Because of M.TB's slow generation 
time, the immune system may not readily recognize the bacteria or 
may not be triggered sufficiently to eliminate them. Many other 
chronic disease are caused by bacteria with slow generation times, for 
example,  slow-growing M. leprae causes leprosy, Treponema 
pallidum causes syphilis, and Borrelia burgdorferi causes Lyme 
disease.  
High lipid concentration in cell wall, as mentioned 
previously, accounts for impermeability and resistance to 
antimicrobial agents, resistance to killing by acidic and alkaline 
compounds in both the intracellular and extracellular environment, 
and resistance to osmotic lysis via complement deposition and attack 
by lysozyme.  
Cord factor: The cord factor is primarily associated with 
virulent strains of M.TB. It is known to be toxic to mammalian cells 
 and to be an inhibitor of PMN migration. However, its exact role in 
M.TB. Virulence is unclear.  
  
Clinical identification and diagnosis of tuberculosis:  
The diagnosis of tuberculosis requires detection of acid-fast 
bacilli in sputum via the Ziehl-Neelsen method as previously 
described.  
The organisms must then be cultured from sputum. First, the 
sputum sample is treated with NaOH. This kills other contaminating 
bacteria but does not kill the M.TB present because M.TB is resistant 
to alkaline compounds by virtue of its lipid layer.  
The media used for growth and the resulting colony 
morphology have been described previously. However, methods of 
culturing can take 4-6 weeks to yield visible colonies. As a result, 
another method is commonly used call the BACTEC System. The 
media used in the BACTEC system contains radio-labeled palmitate 
as the sole carbon source. As M.TB multiplies, it breaks down the 
palmitate and liberates radio-labeled CO2. Using the BACTEC system, 
M.TB growth can be detected in 9-16 days vs. 4-6 weeks using 
conventional media.  
Skin Testing is performed as the tuberculin or Mantoux 
test.  PPD (purified protein derivative) is employed as the test antigen 
 in the Mantoux test. PPD is generated by boiling a culture of M.TB, 
specifically Old Tuberculin (OT).  TU (tuberculin units), which equals 
0.000lmg of PPD, in O.1 ml volume is intracutaneously injected in the 
forearm. The test is read within 48-72 hours.  
Administering the Mantoux test:   
The test is considered positive if the diameter of the resulting 
lesion is 10 mm or greater. The lesion is characterized by erythema 
(redness) and swelling and induration (raised and hard). 90% of 
people that have a lesion of 10 mm or greater are currently infected 
with M.TB or have been previously exposed to M.TB. 100% of people 
that have a lesion of 15 mm or greater are currently infected with 
M.TB or have been previously exposed to M.TB.  
False positive tests usually manifest themselves as lesser 
reactions. These lesser reactions could indicate prior exposure or 
infection with other Mycobacteria or vaccination with BCG. However, 
in places were the vaccine is not used; lesser reactions should be 
regarded as highly suspicious.  
False negatives are more rare than false positives but are 
especially common in AIDS patients as they have an impaired CMI 
response. Other conditions such as malnutrition, steroids .. etc., can 
rarely result in a false negative reaction.  
Tuberculosis treatment:  
 Because administration of a single drug often leads to the 
development of a bacterial population resistant to that drug, effective 
regimens for the treatment of TB must contain multiple drugs to 
which the organisms are susceptible. When two or more drugs are 
used simultaneously, each helps prevent the emergence of tubercle 
bacilli resistant to the others. However, when the in vitro 
susceptibility of a patient's isolate is not known, which is generally the 
case at the beginning of therapy, selecting two agents to which the 
patient's isolate is likely to be susceptible can be difficult, and 
improper selection of drugs may subsequently result in the 
development of additional drug-resistant organisms.  
Hence, tuberculosis is usually treated with four different 
antimicrobial agents .The course of drug therapy usually lasts from          
6-9 months. The most commonly used drugs are rifampin (RIF) 
isoniazid (INH), pyrazinamide (PZA) and ethambutol (EMB) or 
streptomycin (SM). When adherence with the regimen is assured, this 
four-drug regimen is highly effective. Based on the prevalence and 
characteristics of drug-resistant organisms, at least 95% of patients 
will receive an adequate regimen (at least two drugs to which their 
organisms are susceptible) if this four-drug regimen is used at the 
beginning of therapy. Furthermore, a patient who is treated with the 
four-drug regimen, but who defaults therapy, is more likely to be 
cured and not relapse when compared with a patient treated for the 
same length of time with a three-drug regimen.  
 Drugs used to treat TB disease. From left to right isoniazid, rifampin, 
pyrazinamide, and ethambutol. Streptomycin is given by injection.  
Prevention:  
A vaccine against M.TB is available. It is called BCG (Bacillus 
of Calmette and Guerin, after the two Frenchmen that developed it). 
BCG consists of a live attenuated strain derived from Mycobacterium 
bovis. This strain of Mycobacterium has remained avirulent for over 
60 years. The vaccine is not 100% effective. Studies suggest a 60-80% 
effective rate in children.  
The vaccine is not administered in the U.S. for several reasons:  
• The vaccine cannot circumvent disease reactivation in previously 
exposed individuals. 
•  The vaccine does not prevent infection, only disease. Therefore, 
the entire population would have to be vaccinated if the vaccine 
was to be considered efficacious.  
•  Vaccination may complicate the way the tuberculin skin test is 
read in this country. In places that do not vaccinate, the skin test 
may be used to monitor the effectiveness of antibiotic therapy. 
1.4. Anemia associated with tuberculosis and rheumatoid 
arthritis: 
 Anemia is present in 63% of miliary tuberculosis patients. 
There are several reports associating mycobacterial disease with 
anemia, and several mechanisms have been proposed: nutritional 
deficiency, failure of iron utilization, malabsorption syndrome and 
marrow suppression. The association of autoimmune hemolytic 
anemia with tuberculosis, although extremely rare, is known for quite 
long. An early experimental study in Germany showed that the 
injection of tubercle bacilli or their products produce hemolytic anemia, 
pancytopenia and myelofibrosis in small animals. To our knowledge, 
since then, cases of autoimmune hemolytic.(6)  
Anemias in association with tuberculosis have been reported 
in medical history. One case has been reported recently from the 
AIIMS in one of the issues of the Indian Journal of Pediatrics by Bakhshi 
et al4 on autoimmune hemolytic anemia in association with childhood 
tuberculosis. In humans, disseminated tuberculosis may occasionally 
provoke a marked proliferation of reticuloendothelial tissues, 
resulting in varied and severe hematological disorders through 
immune mechanisms.5 Regarding therapy, there are reports in adult 
literature that hemolysis associated with tuberculosis has responded 
to antitubercular therapy alone. Steroids are useful in addition to 
antitubercular therapy if there is severe hemolysis. On the other hand, 
there is a report of autoimmune hemolytic anemia in association with 
miliary tuberculosis that required splenectomy.  
 Anemia in rheumatoid arthiritis patient are most likely to 
anemia of chronic disease, chronic inflammatory, autoimmune 
disease, malnutrition malabsorption or drugs related .Many theories 
or studies were done.   
1.5. Metabolic aspects of folic acid and cobalamin: 
Folate in its tetrahydro form is a transporter of one-carbon 
fragments, which it can carry at any of three oxidation levels: 
methanol, formaldehyde, and formic acid. The oxidation levels of the 
folate-bound one-carbon fragments can be altered in oxidation and 
reduction reactions that require NADP and NAD, respectively. The 
chief source of the folate one-carbon fragments is serine, which is 
converted to glycine as it passes its terminal carbon to folate. The one-
carbon fragments are used for the biosynthesis of purines, thymidine, 
and methionine. During the biosynthesis of purines and methionine, 
free folate is released in its tetrahydro form, but, during the 
biosynthesis of thymidine, the tetrahydrofolate is oxidized to the 
dihydro form and has to be re-reduced by dihydrofolate reductase in 
order to continue to function in one-carbon metabolism (Fig. 1). 
 
  Methotrexate acts as an anticancer agent because it is an 
exceedingly powerful inhibitor of dihydrofolate reductase. 
In the cell, folates are conjugated by the addition of a chain of 6 
or 7 glutamic acid residues. These serve to prevent the folates from 
leaking out of the cell. When folates are absorbed from the intestine, a 
process that takes place chiefly in the duodenum and proximal 
jejunum, all but one of the glutamates is removed by an enzyme 
known as conjugase. Folates travel in the blood stream and are taken 
up by the cells mainly in the form of unconjugated 
methyltetrahydrofolate .In the cell; the newly absorbed folates are 
rapidly reconjugated. If reconjugation is prevented, the folates leak 
back out of the cell, resulting in an intracellular deficiency of folate. 
Cobalamin is required for two reactions: the conversion of 
methylmalonyl CoA (a product of catabolism of branched-chain 
amino acids) to succinyl CoA, a crebs cycle intermediate, and the 
conversion of homocysteine to methionine, a reaction in which the 
methyl group of methyl tetrahydrofolate is donated to the sulfur atom 
of homocysteine. In cobalamin deficiency, methyl-tetrahydrofolate 
accumulates, because for practical purposes donation of the methyl 
group to homocysteine is the only way to generate free 
tetrahydrofolate from methyltetrahydrofolate. Free tetrahydrofolate is 
an excellent substrate for the conjugase, but methyltetrahydrofolate is 
a poor substrate. Consequently, much of the methyltetrahydrofolate 
taken up by a cobalamin-deficient cell leaks out of the cell before it 
 can be conjugated. The megaloblastic anemia of cobalamin deficiency 
is actually due to an intracellular folate deficiency that arises because 
of the limited ability to conjugate methyltetrahydrofolate. 
The absorption of cobalamin is a highly complex process. On 
first arriving in the stomach, cobalamin is taken up by It binder (also 
called haptocotrin or cobalophilin), a glycoprotein that is found in 
virtually all secretions. When the cobalamin-R binder complex enters 
the duodenum, the It binder is digested and the cobalamin is released 
into the intestinal lumen, where it is taken up by intrinsic factor, a 
protein secreted by the gastric parietal cells. The cobalamin-intrinsic 
factor complex is absorbed by cells in the ileum, where the cobalamin 
is released and transported to the blood stream. Here the vitamin 
binds to transcobalamin II, which delivers its cargo of cobalamin to 
cells throughout the body. Folic acid (pteroylglutamic acid) and 
cobalamin (vitamin B play key roles in the metabolic economy of 
proliferating cells. 
1.6. Folic acid chemistry: 
  
Folic acid (pteroylglutamic acid) is composed of a pteridine 
derivative, a p-aminobenzoate residue, and an L-glutamic acid 
residue (Fig.-la). The first two together are called pteroic acid-7. In 
nature, folic acid occurs largely as conjugates which multiple glutamic 
acids are linked by peptide bonds involving their y-carboxyl groups 
(Fig. -2) 
 
 Reduced derivatives of folic acid are usually sensitive to air 
oxidation. An exception of clinical importance is N’-formyl FH also 
called citrovorum factor, leucovorin, and folinic acid. 
 1.6.1. Nutrition sources: 
There are many sources for folic acid. The richest vegetable 
sources are asparagus, broccoli, endive, spinach, lettuce, and beans; 
each contains more than I mg of folate per 100 g dry weight. The best 
fruit sources are lemons, bananas, and melons. Folates are also 
abundant in liver, kidney, yeast, and mushrooms. An average 
dailydiet contain 400-600µg of folate-8. Foods are readily depleted of 
their folate, however, by excessive cooking, especially with large 
amounts of water.  
1.6.2. Daily requirements: 
In the normal adult, the minimum daily requirement for folic 
acid is approximately 50 µg. The average diet contains many times 
this amount, but some may be unavailable. Accordingly, the officially 
recommended daily allowance of food folate for the adult is 0.4 mg.-
9The body is thought to contain approximately 5 mg of folate-10 
when folate intake is reduced to .5µ g/day, megaloblastic anemia 
develops in about 4 months.(11) 
Increased requirements for folic acid occur in hemolytic 
anemia, leukemia, and other malignant diseases; in alcoholism(6) 
during growth; and in pregnancy and lactation, which increase 
requirements threefold to six fold , adequate folate supplies are 
particularly important in pregnant women, in whom the 
recommended intake is 400 µg per day.(12)  
 1.6.3. Folate metabolism: 
Folate-dependent enzymes: 
FH4 is an intermediate in reactions involving the transfer of 
one-carbon units from a donor X—C to an acceptor Y:  
The metabolic systems of animal tissues. 
 
Among the one-carbon transfers mediated by folic acid, the 
one that appears to be clinically the most important is the methylation 
of deoxyuridylate to thymidylate, catalyzed by the enzyme 
thymidylate synthase.(13)This reaction is an essential step in the 
synthesis of DNA. In carrying out this reaction, N5, M10 methylene 
FH4 simultaneously transfers and reduces a one-carbon group, itself 
serving as the hydrogen donor for the reduction. The reaction 
generates FF2, which must be reduced again to FR, by dihydrofolate 
reductase and NADPH before it can again be utilized as a coenzyme:  
 dUMP + N5,N10-methylene FH4 — FH2 + dTMP FH2 + NADPH + H 
— FH4 + NADP.  
Limitation of thymidylate synthesis in folic acid deficiency 
causes uracil to be incorporated into DNA instead of thymine. 
Deficiency of folate also diminishes purine biosynthesis by slowing:                       
(1) The folate-dependent formylation of glycinamide ribotide to N-
formylglycinamide ribotide, the reaction that places the C-8 in the 
purine ring, and  
(2) The folate-dependent conversion of 5-amino-4- imidazole 
carboxamide ribotide (AICAR) to 5-formamido-4-imidazole 
carboxamide ribotide, the reaction that places the C-2 in the 
purine ring. The decrease in purine synthesis, however, is offset 
by the ability of (AICAR) to slow purine degradation by 
inhibiting both adenosine deaminase and adenylate deaminase-7. 
This may explain why no clinical manifestations have thus far 
been traced to the block in purine synthesis. Interference with the 
breakdown of histidine leads to the excretion of 
formininoglutamic acid (FIG1u) in the urine of folate-deficient 
patients. 
 Additional pteridine-dependent reactions of potential 
metabolic importance are the hydroxylation of phenylalanine to 
tyrosine, the oxidation of long-chain alkyl ethers of glycerol to fatty 
acid, the hydroxylation of tryptophan to 6-hydroxytryptophan            
 (a precursor of serotonin), the 17-alfa-hydroxylation of progesterone, 
and the production of nitric oxide (NO).  
1.6.4. Significance of folylpolyglutamates: 
Intracellular folates exist primarily as polyglutamate 
conjugates.14- About 75 percent of the folate in human erythrocytes 
and leukocytes is conjugated .Plasma folate, however, consists almost 
exclusively of the monoglutamate N’-methyl FH and is transported 
into the cells in this form. Inside the cells, the polyglutamate chain is 
added by an ATP-dependentfolylpoly-glutamyl synthase.  
Intracellular folylmonoglutamates leak out of the cells at a 
fairly rapid rate, while the polyglutamates do not, presumably 
because of the highly charged polyglutamate tail-15. Attachment of 
the polyglutamate chain is therefore essential for retaining folates 
within cells. Moreover, folylpolyglutamates are superior to 
monoglutamates as substrates for folate-dependent enzyme reactions. 
 
1.6.5. Physiology:  
1.6.5.1. 1intestinal absorption: 
The proximal jejunum is the principal site of folate absorption. 
Absorption of a dose of either unconjugated or conjugated folate 
begins within minutes, and peak levels are reached in 1 to 2 hour. 
Since only folylmonoglutamate appears in plasma, all 
 folylpolyglutamates are deconjugated during absorption across the 
intestine.(16,17) 
Deconjugating enzymes (conjugases) play an important but 
poorly understood role in the intestinal absorption of folate. 
Folylpolyglutamate may be hydrolyzed within the lumen of the 
intestine, and the monoglutamate product may be absorbed 
subsequently. Alternatively, hydrolysis may occur at the brush border 
of the intestinal cell.  
Conjugases are not found only in the intestine. Human plasma, 
for example, contains sufficient conjugase to convert polyglutamates 
containing more than three glutamyl residues to monoglutamates*. 
Once deconjugated, the folates are actively transported across the 
intestinal epithelium by a carrier-mediated mechanism that is 
independent of Na, K, and transmembrane potential. This mechanism 
uses the pH gradient between the jejunal lumen (pH—6) and the 
interior of the epithelial cell to drive folate into the cell against a 
concentration gradient. Passive transport may also occur. In the 
intestinal cell, the absorbed folate monoglutamates are reduced if 
necessary, then converted to N5-methyl FH4 (some N10- formyl FH4 is 
made as well) and transported into the bloodstream without further 
change. Folate has been shown to undergo an enterohepatic cycle in 
which it is first secreted against a concentration gradient into the bile, 
appearing there chiefly as N5-methyl FH4 monoglutamate, and is then 
reabsorbed from the small intestine. Bile contains approximately 2 to 
 10 times the folate concentration of normal serum, with biliary 
excretion accounting for up to 0.1 mg of folate per day. This quantity 
is large enough that the interruption of the enterohepatic cycle by 
biliary diversion causes serum folate levels to fall by over 50 percent 
in less than a day. It has been proposed that the enterohepatic cycle 
serves to redistribute folate between hepatic stores and peripheral 
tissues according to the state of the exogenous folate supplies, this 
view, however, has been disputed.  
1.6.5.2. Excretion: 
Folates are both resorbed and secreted by the kidney. 
Resorption is accomplished by means of a membrane-bound high-
affinity folate receptor (Km for N5-methyl FH4 = 0.4 nM) located in the 
brush borders of the proximal tubules. Filtered folate is carried 
rapidly by this receptor into the proximal tubule cell and from there 
makes its way slowly into the bloodstream. At the same time, folate is 
secreted into the proximal tubule by a nonspecific probenecid-
sensitive organic anion carrier that is closely related, or identical to the 
membrane transporter, and is also responsible for the renal secretion 
of p-aminohippuric acid (which blocks renal folate secretion), 
penicillin, and uric acid. The net result of these two processes is the 
resorption of most of but not all the filtered folate. In humans, intact 
folates and their cleavage products are excreted by the kidney at a rate 
of 2 to 5 µg/day. Folates given in doses lower than 15 pg/kg are 
excreted in the urine in reduced forms, particularly as N10-formyl 
 FH4. With doses of folate greater than 15 ug/kg, large amounts are 
excreted unchanged.  
A small percentage of parenterally administered 3H-F is 
recoverable in the feces. This mainly represents overflow from the 
enterohepatic cycle discussed above. 
1.6.6. Assay of serum folate: 
Microbiological assays for folate were in use for many years. 
Now, however, they have been largely supplanted by isotopic 
methods employing various folate binders. These isotopic folate 
assays are identical in principle to radioimmunoassays. 
1.7. Cobalamin chemistry: 
1.7.1. Structure and nomenclature:  
The cobalamin molecule has two major portions: a porphyrin-
like near- planar macrocycle known as corrin and a nucleotide that 
lies almost perpendicular to the corrin ring (Fig. 3). 
  
 The corrin moiety contains four reduced pyrrole rings, that 
bind a central cobalt atom whose two remaining coordination 
positions are occupied by a 5,6-dimethyl- benzimidazolyl group 
(below the ring) and various ligands (above the ring; in this case, CN) 
Compounds containing the coffin ring are known as corrinoids. The 
cobalamins are corrinoids whose nucleotide contains, 5, 6-
dimethylbenzimidazole. There are two connections between the 
corrin and the nucleotide: (1) a bond between the nucleotide 
phosphate and a side chain in ring D and (2) a bond between cobalt 
and a nitrogen atom of benzimidazole. The numbering and ring 
designations of the corrin system are summarized in (Fig. 5).  
  
The term vitamin B12 is sometimes employed as a generic term 
for the corrinoids. It is probably best reserved, however, as an 
alternative name for cyanocobalamin, the usual therapeutic 
corrinoids. 
Four cobalamins are of importance in animal cell metabolism. 
Two are cyanocobalamin (CNCbI; vitamin) and hydroxocobalamin 
(OHCbl). The other two are alkyl derivatives that are synthesized 
from hydroxocobalamin and serve as coenzymes. In one, 
adenosylcobalamin (AdoCbl), a 5-deoxyadenosyl replaces OH as the 
cobalt ligand above the ring. In the second, methylcobalamin (MeCbl), 
the upper ligand is a methyl group. Methylcobalamin is the major 
form of cobalamin in human blood plasma. 
1.7.2. Nutrition sources: 
Cobalamin is synthesized only by certain microorganisms and 
animals depend ultimately on microbial synthesis for their cobalamin 
supply. Foods that contain cobalamin are those of animal origin: meat, 
 liver. Seafood and dairy products. Cobalamin has not been found in 
plants. 
1.7.3. Daily requirements: 
The average daily diet in Western countries contains 5 to 30 g 
of cobalamin. Of this, it is 1-5 µg absorbed-18. Less than 250 ng 
appears in the urine; the unabsorbed remainder appears in the feces. 
Total body content is 2 to 5 mg in an adult, with approximately1 mg 
in the liver. The kidneys are also rich in cobalamin. Relative to the 
daily requirement, body reserves of cobalamin are much larger than 
those of folate. 
Cobalamin has a daily rate of obligatory loss of approximately 
0.1 percent of the total body pool, irrespective of the pool size. For this 
reason, a deficiency state will not develop for several years after the 
cessation of cobalamin intake. The officially recommended daily 
allowance for adults is 5 µg for growth, hypermetabolic states, and 
pregnancy increase daily requirements. For infants during the first 
year the recommended daily allowance is 1 to 2 µg. In cobalamin 
deficient subjects, a normal diet containing about 15 µg per day will 
replenish depleted body stores. 
 1.7.4. Role in metabolism: 
The only two recognized cobalamin-dependent enzymes in 
human cells are adenosylcobalamin-dependent methylmalonyl CoA 
mutase and methylcobalamin-dependent methyltetrahydrofolate-
 homocysteine methyltransferase. The presence in humans of a third 
cobalamindependent enzyme, Lucien 2, 3-aminomutase, is 
controversial.  
Methylmalonyl CoA mutase: 
The coenzyme serves as an intermediate hydrogen carrier. 
Accepting the hydrogen from the substrate in the initial phase of the 
reaction, and returning it to the product after the migration of — 
COSCoA. The place for the migrating hydrogen is created by the 
cleavage of the carbon-cobalt bond to form cob (II) alamin and the 5’- 
deoxyadenos-5’-yl radical at the active site of the enzyme. This is one 
of the few examples of an enzyme-catalyzed reaction mediated by an 
active-site free radical situated on an unactivated carbon. The enzyme 
is encoded by a gene on chromosome 6.(19,20) 
• N5-methyltetrahydrofolate: homocysteine methyltransferase:  
Methylcobalamin participates in the cobalamin-dependent 
synthesis of methionine according to the scheme shown in (Fig. 2)(21-
22-23). S-adenosylmethionine and methionine synthase reductase are 
for methyltransferase activity, probably to reactivate enzyme 
molecules whose coenzyme has become inactivated by oxidation of 
the cobalt. The reductase converts the oxidized cobalt to the readily 
alkylatable Co+, which then accepts a methyl group from S-
adenosylmethionine, a powerful biological methylating agent, thereby 
restoring the activity of the methyltransferase. In humans this 
 pathway also serves as a mechanism for converting N5-
methyltetrahydrofolate to tetrahydrofolate. The demethylation of N5-
methyl FH4 is a prerequisite for the attachment of the polyglutamate 
chain to newly acquired folate, which is largely taken up by the cell in 
the form of N5-methyl FH4 monoglutamate? Nitrous oxide (N2) 
impairs the methyltransferase by oxidizing cob (I) alamin (a catalytic 
intermediate in the methyltransferase reaction) to cob, (ll) alamin. This 
depletes Me Cbland produces a cobalamin deficiency—like state. 
 
 
1.7.5. The folate-cobalamin relationship: 
  In both folate deficiency and cobalamin deficiency, the 
megaloblastic anemias are fully corrected by treatment with the 
appropriate vitamin.  The megaloblastic anemia of cobalamin 
deficiency is also largely corrected by folic acid supplementation even 
if no cobalamin is given, while, conversely, the anemia of folate 
deficiency is not helped at all by cobalamin. These clinical 
observations indicate that in cobalamin deficiency, the megaloblastic 
anemia is actually a result of an abnormality in folate metabolism. 
Further evidence that folate metabolism is deranged by cobalamin 
deficiency is provided by the observation that urinary excretion of 
FIGIu and AICAR, normally regarded as a sign of folate deficiency, is 
seen occasionally in pure cobalamin deficiency.(24)Two explanations 
have been offered to account for the folate responsiveness of 
cobalamin-deficient megaloblastic anemia: the methylfolate trap 
hypothesis, which has been accepted by the majority of authorities, 
and the formate starvation hypothesis (Fig. 25-13).  
The Methylfolate Trap Hypothesis 
 
  The methylfolate trap hypothesis is based on the fact that the 
folate-requiring enzyme N5-methyl FH4 homocysteine 
methyltransferase is also dependent on cobalamin. This hypothesis 
states that in cobalamin deficiency, tissue folates are gradually 
diverted into the N5-methyl FH pool because of the slowing of the 
methyltransferase reaction,(25,26)the only route out of that pool for 
folate. As N5-methyl FH, levels increase, levels of the other forms of 
folate decline, with a consequent fall in the rates of reactions in which 
those forms participate. In particular, the synthesis of dTMP is 
slowed, and megaloblastic anemia ensues. 
In its simplest form, this hypothesis predicts that in cobalamin 
deficiency, tissue levels of N5-methyl FH4 should be abnormally high 
and those of other forms of folate should be abnormally low. 
Although serum N’-methyl FH4 levels are elevated in cobalamin 
deficiency, tissue folate levels actually decline, while increases in the 
fraction of tissue folates in the form of N5-methyl FH4 may or may not 
occur. The folates whose relative levels do consistently fall as total 
folate levels decline are the polyglutamates?  Their fall appears to be 
related to the substrate specificity of the folate-conjugating enzyme. 
This enzyme works very poorly with N5-methyl FH4 and is therefore 
unable to carry out normal y-glutamylation of newly internalized N5-
methyl FH4 monoglutamate in cobalamin-deficient cells because the 
freshly acquired folate cannot be converted into a suitable substrate 
(i.e. free FH4, or formyl FH4). Thus, while sequestration of tissue 
 folates in an expanded N5-methyl FH4 pool may account for some of 
the effects of the blockade in methyltransferase activity, the major 
problem seems to be a failure to convert newly acquired folate into a 
form that can be retained by the cell, the upshot being the 
development of a tissue folate deficiency as the unconjugated folate 
leaks out.  
This whole process is aggravated by a drop in tissue levels of-
adenosylmethionine as the methionine supply is curtailed because of 
the diminished activity of the methyltransferase. 
S-adenosylmethionine, which is necessary for methyl-
transferase activity as discussed above, is also a powerful inhibitor of 
N5, N10-methylene FH4 reductase, the enzyme responsible for the 
production of N5-methyl FH4.The relief of this inhibition as                         
S-adenosylmethionine levels fall accelerates the flow of folates toward 
N5- methyl FH4, further aggravating the metabolic imbalance that 
results from the impairment in methyltransferase activity. This 
problem could be overcome if N5-methyl FH4 could be converted into 
a substrate for the conjugating enzyme by another route. In theory, 
this could be accomplished by the reversal of the N5, N10- methylene 
FH4 reductase reaction or by the catabolism of N5-methyl FH4 via the 
methylation of biogenic amines. In fact, however, the N5, N10-
methylene FH4 reductase reaction is for practical purposes irreversible 
in vivo, and the methylation of biogenic amines by N5- methyl FH4 is 
too slow to provide much relief.  
  
 
The Formate Starvation Hypothesis: 
 This hypothesis holds that formate starvation is the basis for 
the folate-responsive megaloblastic anemia of cobalamin deficiency. 
This theory is based on the diminished capacity of cobalamin-
deficient lymphoblast to incorporate formaldehyde into purine and 
methionine and on experiments showing that N5’-formyl FH4 is more 
effective than FH4 at correcting some of the abnormalities in folate 
metabolism seen in cobalamin deficiency. The hypothesis states that 
with the fall in methionine production in cobalamin-deficient states, 
the generation of formate is depressed (since normally the methyl 
group of excess methionine is rapidly oxidized to format and leading 
to a decline in the production of N5-formyl FH4. If N5-formyl FH4 but 
not FH, is a substrate for the conjugating enzyme, then the low tissue 
folate levels seen in cobalamin deficiency cannot be due merely to 
impaired demethylation of N5-methyl FH4 by a cobalamin-deficient 
homocysteine methyltransferase but must reflect a decreased 
production of methionine, the source of the formate needed to 
produce the conjugatable substrate, N5 formyl FH4. 
1.7.6. Physiology:  
1.7.6.1. Intestinal absorption: the intrinsic factor mechanism: 
 Intrinsic factor is one of a number of proteins to which 
cobalamin bound as it makes its way through the body. Intrinsic 
factor is needed for the absorption of cobalamins given orally all 
physiologic dosage levels. Human intrinsic factor is a glycoprotein  
(M approximately 44,000) encoded by a gene on chromosome ll. It has 
binding sites for cobalamin and for a specific ileal receptor, the former 
situated near the carboxy terminus and the latter near the amino 
terminus of the intrinsic factor molecule.(27) Binding to cobalamin is 
very tight. Its properties are summarized in. 
Bound vitamin alters the conformation of intrinsic factor, 
producing a more compact form that is resistant to proteolytic 
digestion. In humans, intrinsic factor is synthesized and secreted by 
the parietal cells of the cardiac and fundic mucosa. Secretion of 
intrinsic factor usually parallels that of HCI. It is enhanced by the 
presence of food in the stomach, by vagal stimulation, and by 
histamine and gastrin. 
Gastric juice also contains other cobalamin-binding proteins. 
These are known as the R binders because of their rapid 
electrophoretic mobility compared with intrinsic factor. The R binders 
are a group of immunologically related proteins of apparent M 
approximately 60,000 consisting of a single polypeptide species 
variably substituted. 
With oligosaccharides that terminate with different quantities 
of sialic acid. These proteins are found in milk, plasma, saliva, gastric 
 juice, and numerous other body fluids. They appear to be synthesized 
by mucosal cells of the organs that secrete them and by phagocytes. 
Though they bind cobalamin, they lack intrinsic factor activity, i.e. 
they are unable to promote the intestinal absorption of the vitamin. 
Cobalamins in foods are liberated in the stomach by peptic 
digestion.They are then bound not to intrinsic factor but to R binders, 
because, at the acid pH of the stomach, cobalamin binds much more 
tightly to R binders than to intrinsic factor. On entering the 
duodenum, cobalamin is released from the cobalamin—R binder 
complex by digestion with pancreatic proteases, which in normal 
subjects act by selectively degrading R binders and the cobalamin—R 
binder complex while sparing intrinsic factor. It is at this point that the 
cobalamin finally reaches the intrinsic factor to form the intrinsic 
factor- cobalamin complex. 
The intrinsic factor-cobalamin complex, which is very resistant 
to digestion. Then journeys down the intestine until it reaches the 
intrinsic factor receptor cubulin, a 460-kDa peripheral membrane 
protein that is located in the microvillus pits of the ileal mucosa. (The 
same receptor is found in the brush border of renal proximal tubule 
cells. Its purpose there is unknown.) The ileal mucosa occupies the 
distal half of the small intestine, and the cubulin is found all along this 
portion of the intestine, its concentration rising progressively until a 
maximum is reached near the terminal ileum. A specific site on the 
intrinsic factor molecule avidly attaches to the receptor in a binding 
 reaction that requires a pH of 5.4 or greater and Ca2 (or other divalent 
cations) but no energy. Following attachment of intrinsic factor—
cobalamin to receptor, the vitamin is taken into the ileal mucosal cells 
over 30 to 60 mm by enclocytosis,’6’ then over many hours is passed 
by the mucosal cells into the portal blood, while the receptors recycle 
to the surfaces of the microvilli for another load of intrinsic factor—
cobalamin. During its sojourn in the ileal enterocyte the vitamin first 
appears in the lysosomes, but by 4 hours most of it is located in the 
cytosol. During absorption the entire intrinsic factor—cobalamin 
complex appears to be taken into the cell, where the cobalamin is 
released while the intrinsic factor is degraded. It requires 3 to 4 h for 
the cobalamin from a small oral dose (10 to 20 g) to start to appear in 
the blood and 8 to 12 h for the vitamin to reach a peak level. In the 
portal blood, the cobalamin is complexed with a cobalamin-
transporting protein known as transcobalamin II (TC II). The 
cobalamin—TC II complex is probably formed in the ileal enterocyte, 
one of a variety of cells that have been shown to synthesize the 
transcobalamin. Large oral doses (1 mg) of cobalamin are absorbed by 
simple diffusion that is not mediated by intrinsic factor. In these 
instances, vitamin appears in blood within minutes, again as the 
cobalamin—TC II complex.  
Like the folates, the cobalamin participates in an enterohepatic  
cycle. In humans, between 0.5 and 9 g/day of cobalamins is secreted 
into the bile, where the cobalamins bind to an R binder and enter the 
 intestine. In the intestine, the cobalamin—R binder complexes of 
biliary origin are treated exactly like those delivered from the 
stomach: The cobalamin is released by digestion of the R binder by 
pancreatic proteases then is taken up by intrinsic factor and 
reabsorbed. It has been estimated that 65 to 75 percent of the biliary 
cobalamin is reabsorbed by this mechanism. Because of the size of the 
cobalamin storage pool and the existence of this enterohepatic 
circulation, it takes a very long time—sometimes 20 years—to develop 
clinically significant cobalamin deficiency from a diet providing 
insufficient cobalamin (e.g. a strictly vegetarian diet). Patients who fail 
to absorb the vitamin, however, become clinically deficient in only 3 
to 6 years, because biliary as well as dietary cobalamin is lost. 
1.7.6.2. Cobalamin in the cell: transcobalamin II: 
The Uptake of Cobalamin by Cells Transcobalamin II (TC II) is 
the plasma protein that mediates the transport of cobalamin into the 
tissues. A simple protein of M =43,000, it binds cobalamin with 
exceedingly high affinity cobalamin TC II is synthesized by many 
types of cells, including enterocytes, hepatocytes, mononuclear 
phagocytes, fibroblasts, hematopoietic precursors in the marrow, and 
probably others. Although circulating TC II carries only a minor 
fraction of the cobalamin in the plasma, it is the protein to which 
newly acquired cobalamin is first bound. Cobalamin given 
parenterally associates almost immediately with unsaturated TC 
while cobalamin absorbed through the intestine is probably carried 
 into the portal blood as the preformed cobalamin—TC II complex. 
Within minutes after their appearance in the bloodstream, these 
cobalamin—TC II complexes are transported into the tissues. The 
transport process begins with the binding of the cobalamin—TC II 
complex to a membrane receptor that is present on a wide variety of 
cells. The receptor-bound complex is then internalized by pinocytosis 
and delivered to a lysosome. Where the TC 11 is digested and the 
cobalamin is freed. The cobalamin is then actively exported from the 
lysosome into the cytosol by a specific Mg2- dependent carrier (Km for 
CNCb1=3.5 MM) that uses a proton gradient as the energy source). 
Plasma cobalophilins: transcobalamins I and III: 
Transcobalamin I (TC I) is the principal R binder of plasma 
and carries most of the circulating cobalamin. It is a glycoprotein of 
M, approximately 50,000 containing nine potential glycosylation 
sites20° and is encoded by a gene on chromosome I, the same 
chromosome that carries the intrinsic factor gene. In contrast to TC II, 
its clearance from the plasma is very slow (9 to 10 days). The 
cobalamin—TC I complexes are eliminated chiefly by the hepatocytes, 
into which they are carried by the asialoglycoprotein receptor, there to 
be degraded and their load of cobalamins excreted in the bile. TC I 
binds its ligands more tightly than does either intrinsic factor or TC II 
and is less restrictive than either with respect to ligand specificity, 
avidly taking up corrinoids of widely varying structure. The ligand 
binding properties of TC 1, together with its mode of clearance by the 
 liver, have led to the suggestion that TC I helps clear the system of 
nonphysiologic cobalamin analogs that may be accidentally acquired 
in the normal course of events. As the liver metabolizes analog—TC I 
complexes, it will secrete the analogs into the bile. Since these analogs 
are bound poorly by intrinsic factor, they will be poorly reabsorbed 
from the intestine and instead will be eliminated in the feces. An 
alternative proposal is that TC I is a storage protein for cobalamins.In 
reality, however, the physiologic role of TC I is unknown. A second 
circulating R binder is known as transcobalamin III (TC III).This 
protein is found in the plasma as well as in granulocytes, where it 
constitutes the cobalamin-binding protein of the specific granules and 
from which it is released into the serum when blood clots. 
Structurally, TC I is richer in sialic acid than is TC III. It is likely that 
the plasma R binders actually consist of half a dozen or more species 
whose p1 values range from 2.9 to 4.0, with TC I” and “TC III” 
representing the arbitrary division of these R binders into a low-pI 
group and a high-pi group. 
1.7.6.3. Assay of serum cobalamin and the transcobalamins: 
Cobalamin As with folate, cobalamin is measured using a 
radioisotope assay employing a cobalamin-binding protein. The 
misleading results formerly given by this assay were explained by the 
discovery in serum and tissue of a class of cobalamin analogs that are 
detected by the radioisotope assay when the binder is R binder but 
not when intrinsic factor is used as the binder. Current assays use 
 intrinsic factor as binder and give accurate values for serum 
cobalamin. The chemical nature and biological significance of the 
analogs are unknown. The transcobalamin TC I and TC II are present in 
plasma in trace quantities (about 7 and 20 micro/g/Liter, 
respectively), while TC Ill is often undetectable. In fasting plasma, 70 
percent or more of the circulating cobalamin is bound to TC. 
Nevertheless; TCI has substantial unsaturated binding capacity. TC II 
binds only 10 to 25 percent of the total plasma cobalamin but provides 
the majority (about 75 percent) of the total unsaturated cobalamin-
binding capacity of plasma. Less than 2 percent of the TC II in plasma 
is saturated at any given moment. Alterations in unsaturated 
cobalamin-binding capacity and in TC I and TC II levels in various 
disease states are listed in (Table 5).  
 
1.8. The megaloblastic anemias: 
 Megaloblastic anemia is most commonly due to a deficiency of 
folate or cobalamin (vitamin B12). Folate deficiency is usually 
nutritional in origin and may be seen in alcoholics and the elderly 
poor but also in patients on hyperalimentation or hemodialysis. In 
pregnancy, even a mild folate deficiency is associated with defects in 
neural tube closure in the fetus, so folate supplements should  
 always be given to pregnant women. Diagnosis is based on 
measurements of folate in serum, which furnishes information about 
the current level of folate, and in red cells, which provides data on 
folate levels over the preceding 6 weeks. Nutritional folate deficiency 
is treated with folic acid by mouth. 
Folate deficiency due to malabsorption occurs in tropical and 
nontropical sprue .Folate deficiency due to tropical sprue is treated 
with folate supplements plus antibiotics; in nontropical sprue, the 
treatment is folate plus a gluten- free diet.  
The commonest cause of cobalamin deficiency is pernicious 
anemia, a condition in which the portion of gastric mucosa that 
contains the parietal cells is destroyed through an autoimmune 
mechanism. The parietal cells secrete intrinsic factor, which is 
essential for cobalamin absorption, and without intrinsic factor a state 
of cobalamin deficiency develops over the course of years. Cobalamin 
deficiency leads not only to megaloblastic anemia but also to a 
demyealinating disease that manifests itself as peripheral neuropathy 
spastic paralysis with ataxia (so-called combined system disease of the 
 spinal cord), dementia, psychosis, or combination of the foregoing. 
“Subtle” cobalamin deficiency, manifested as neurologic symptoms 
without anemia, appears to be relatively widespread among the 
elderly. 
The incidence of gastric cancer is increased by a factor of 2 to 3 
in patients with pernicious anemia. Other causes of cobalamin 
deficiency are gastric resection; stasis of the small intestinal contents 
due to blind loops, strictures, or hypomotility (seen, for example, in 
amyloid); or disease or resection of the terminal ileum. Patients on a 
vegan diet will also become cobalamin deficient. The diagnosis of 
cobalamin deficiency is made by measuring the level of the vitamin in 
the blood or by measuring serum methylmalonic acid, which 
accumulates in the blood stream in patients with cobalamin 
deficiency. The cause of the cobalamin deficiency can often be 
determined by the Schilling test, a measure of cobalamin absorption. 
In patients with nutritional megaloblastic anemia, it is of great 
importance to establish whether the anemia is due to folate deficiency 
or cobalamin deficiency, because if a patient with cobalamin 
deficiency is treated with folic acid, the anemia will be corrected but 
the neurologic abnormalities will progress. Patients with cobalamin 
deficiency are usually treated with parenteral cobalamin.  
Megaloblastic anemia can develop as an acute disorder with rapid 
development of leukopenia and/or thrombocytopenia. Nitrous oxide 
anesthesia is responsible for some cases of acute megaloblastic 
 anemia. It is also seen in patients with a marginal folate status in 
intensive care units. Acute myeloblastic leukemia of the M6 type             
(Di Guglielmo’s syndrome). The anemia of refractory megaloblastic 
anemia sometimes responds to pyridoxine in very. The condition 
resembles an immune cytopenia, but this can be ruled out by 
examining the bone marrow, which exhibits a floridly megaloblastic 
picture. Other causes of megaloblastic anemia include drugs (e.g. 
hydroxyurea, nucleoside analogs) and certain inborn errors of 
metabolism. Of these inherited conditions, transcobalamin II 
deficiency is singled out because it causes a severe megaloblastic 
anemia in infants that responds completely to high-dose cobalamin; if 
it is not detected in time, however, irreversible neurologic 
complications will supervene. Finally, megaloblastic anemia is seen in 
refractory megaloblastic anemia, a form of the myelodysplastic 
syndrome, and in early stages of high doses.  
1.8.1. General considerations:  
Definition: Megaloblastic anemias are disorders caused by 
impaired DNA synthesis and characterized by the presence of 
megaloblastic cells, the morphologic hallmark of this group of 
anemias. Megaloblastic red cell precursors are larger than normal and 
have more cytoplasm relative to the size of the nucleus. 
Promegaloblasts show a blue granule-free cytoplasm and a granular 
chromatin that contrasts with the ground- glass texture of its normal 
counterpart. As the cell differentiates, the chromatin condenses more 
 slowly than normal into dark aggregates that coalesce to give the 
nucleus a characteristic fenestrated appearance. Condensation of the 
chromatin to a homogeneous mass either fails or is delayed. As the 
cytoplasm acquires hemoglobin, its growing maturity contrasts with 
the immature-looking nucleus, a feature termed nuclear-cytoplasmic 
asynchrony. 
Megaloblastic granulocyte precursors are also larger than 
normal and show nuclear-cytoplasmic asynchrony, with cytoplasm 
that looks less mature than that of their normal counterparts. A 
characteristic cell is the giant metamyelocyte, with a large horseshoe-
shaped nucleus, sometimes irregular in shape, containing ragged 
chromatin. Megaloblastic megakaryocytes may be abnormally large, 
with deficient granulation of the cytoplasm. In severe megaloblastosis, 
the nucleus may show unattached lobes.  
1.8.2. Clinical features:  
All megaloblastic anemias share certain general clinical 
features. Because the anemia develops slowly, it produces few 
symptoms until the hematocrit is severely depressed. When 
symptoms appear, they are those of anemia: weakness, palpitation, 
fatigue, light-headedness, and shortness of breath. Severe pallor and 
slight jaundice combine to produce a telltale lemon-yellow skin. 
Leukocyte and platelet counts may also be low but rarely cause 
clinical problems. Details of the clinical manifestations are given in the 
sections on the specific forms of megaloblastic anemia later in this 
 chapter.  
1.8.3. Laboratory features:  
1.8.3.1. Blood cells: All cell lines are affected. Erythrocytes vary 
markedly in size and shape, are often large and oval, and in severe 
cases can show basophilic stippling and nuclear remnants (Howell-
Jolly bodies, Cabot rings). The reticulocyte count is low. The more 
severe the anemia, the more pronounced the morphologic changes in 
the red cells. When the hematocrit is less than 20 percent, red cells 
with megaloblastic nuclei, including an occasional promegaloblast, 
may appear in the blood. The anemia is macrocytic (MCV 100 to 150 fl 
or more), although coexisting iron deficiency, thalassemia trait, or 
inflammation can prevent macrocytosis.(28)Slight macrocytosis is often 
the earliest sign of megaloblastic anemia. 
Neutrophil nuclei often have mere than the usual three to five 
lobes (Fig. 1).(29) Typically, more than 5 percent of the neutrophils 
have five lobes, and cells may appear containing six or more lobes, 
morphology never seen in normal neutrophils. In nutritional 
megaloblastic anemias, hypersegmented neutrophils are an early sign 
of megaloblastosis and persist in the blood for many days after 
treatment. Chromosomes are elongated and broken. Specific therapy 
corrects these abnormalities, usually within 2 days, though some take 
months to disappear. Platelets are slightly smaller than normal and 
vary more widely in size (increased PDW).(30)  
 1.8.3.2 Marrow: Aspirated marrow is cellular and shows 
striking megaloblastic changes, especially in the erythroid series. 
Sideroblasts are increased in number and contain increased numbers 
of iron granules. The ratio of myeloid to erythroid precursors (MIE 
ratio) falls to 1:1 or lower, and granulocyte reserves may be 
decreased.(31) In severe cases, promegaloblasts containing an 
unusually large number of mitotic figures are plentiful. Macrophage 
iron content is often increased.(31) 
1.8.3.3. Megaloblastic Anemia Misdiagnosed as Acute 
Leukemia Occasionally, very severe megaloblastic anemia may 
produce marrow morphology so bizarre as to be mistaken for acute 
leukemia, especially if the marrow lacks classical megaloblasts and 
displays principal cell type the bizarre megaloblastic white cell 
precursors that in a more typical morphologic background would 
support the diagnosis of a megaloblastic anemia. In some cases, there 
is no maturation of the erythroid series, and the megaloblastic 
pronormoblast dominates the marrow, raising the possibility of 
erythroid leukemia.  
1.8.3.4. Megaloblastic changes in other cells: In most forms of 
megaloblastic anemia, cytologic abnormalities resembling 
megaloblastosis may appear in other proliferating cells. Epithelial 
cells from the mouth, stomach, small intestine, and cervix uteri may 
look megaloblastic, appearing larger than their normal counterparts 
and containing atypical immature-looking nuclei. It is sometimes 
 difficult to distinguish these “megaloblastic” changes from those of 
malignancy.  
1.8.3.5. Cytokinetic: Megaloblastic anemia is associated with 
two pathophysiology abnormalities: ineffective erythropoiesis and 
hemolysis. Ineffective erythropoiesis causes increases in the red cell 
precursor/reticulocyte ratio, plasma iron turnover, LDH-l and LDH-
2,(32) and “early-labeled” bilirubin. Extramedullary hemolysis also 
occurs in megaloblastic anemia, with red cell life span decreased by 30 
to 50 percent.(33) 
Increased serum muramidase in megaloblastic anemia may be 
caused by increased granulocyte turnover, possibly induced by the 
disintegration of granulocyte precursors in the marrow (ineffective 
granulopoiesis). In cobalamin deficiency, platelet production is only 
10 percent of that expected from the Megakaryocyte mass, perhaps 
reflecting ineffective thrombopoiesis. Platelets in severe cobalamin 
deficiency are functionally abnormal. 
 
Classification of the megaloblastic anemias: 
Folate deficiency: 
- Decreased intake poor nutrition. 
- Old age, poverty, alcoholism. 
 - Hyperalimentation. 
- Hemodialysis.  
- Premature infants,   children on synthetic, diets Goat’s 
milk anemia. 
- Impaired absorption.  
- Nontropical sprue. 
- Tropical sprue.  
- Other disease of the small intestine.  
- Increased requirements. 
- Pregnancy. 
- Increased cell turnover.  
- Chronic hemolytic anemia. 
- Exfoliative dermatitis. 
Cobalamin deficiency:  Impaired absorption 
Gastric causes:  
 - Pernicious anemia.  
- Gastrectomy. 
- Zollinger-Ellison syndrome.  
 Intestinal causes: 
- Ileal resection or disease.  
- Blind loop syndrome. 
- Fish tapeworm. 
- Pancreatic insufficiency. 
 - Decreased intake. 
 - Vegetarianism.  
- Acute megaloblastic anemia. 
- Nitrous oxide exposure. 
  Severe illness with: 
  - Extensive transfusion.  
  - Dialysis. 
Total parenteral nutrition  
Exposure to weak folate antagonists (e.g., trimethoprim or 
low-dose   methotrexate).  
Drugs:  
Dihydrofolate reductase inhibitors, antimetabolites, inhibitors 
of deoxynucleotide synthesis, miscellaneous, anticonvulsants and oral 
contraceptives.  
   Others: 
- Inborn errors cobalamin deficiency.  
- lmerslund-Gr disease. 
-  Congenital deficiency of intrinsic factor and tanscobalamin II 
deficiency. 
-  Errors of folate metabolism. 
-  Congenital folate malabsorption. 
-  Dihydrofolate reductase deficiency. 
-  N’-methyl FH4: homocysteine methyltransferase deficiency. 
-  Errors of cobalamin metabolism “Cobalamin mutant” syndromes 
with homocysteinuria". 
-  Hereditary orotic aciduria. 
-  Lesch-Nyhan syndrome. 
-  Thiamine-responsive megaloblastic anemia. 
- Unexplained congenital dyserythropoietic anemia. 
-  Refractory megaloblastic anemia. 
-  Erythroleukemia.  
1.8.4. Folic acid deficiency:  
          Aetiology and pathogenesis: 
 Folate deficiency is caused by (1) dietary deficiency, (2) 
impaired absorption, and (3) increased requirements. A decreased 
intake caused by poor nutrition. An inadequate diet is the major cause 
of folate deficiency.  
1.8.4.1. Laboratory features: 
The earliest indicator of folate deficiency is a low serum folate. 
Serum folate follows folate intake closely, so a low serum (below 
about 3 ng/ml) may indicate only a drop in folate intake over the 
preceding few days. Similarly, a low serum folate will rise quickly on 
refeeding, so serum should be frozen early in case a later assay is 
necessary.(34)  
A better indicator of the tissue folate status is the red cell 
folate,(34) which remains relatively unchanged while a red cell is 
circulating and thus reflects folate turnover over the preceding 
months. Red cell folate is usually quite low in folate-deficient 
megaloblastic anemia. It is also low, however, in more than of patients 
with cobalamin-deficient megaloblastic anemia,(35) and therefore 
cannot be used to distinguish between these deficiencies. Conversely, 
red cell folate may be normal in the megaloblastic state that occurs, 
often with little accompanying anemia, in rapidly developing folate 
deficiency.  
 The dU suppression test is used in research on pathogenetic 
mechanisms in megaloblastic states. It adds little to the clinical 
evaluation of a megaloblastic anemia.  
1.8.4.2. Nonhematologic effects of folate deficiency:  
The hematologic problems associated with folate deficiency 
have been recognized for decades. Recently, however, folate 
deficiency has been related to a number of serious disorders not 
involving the hematopoietic system. These disorders, moreover, are 
seen at folate levels usually regarded as low-normal. They include 
congenital anomalies, fragile site syndromes, and, most common of 
all, atherosclerosis.  
1.9. Cobalamin deficiency:  
1.9.1. Aetiology and pathogenesis: 
A decreased uptake caused by impaired absorption  
Cobalamin deficiency is most often a result of defective absorption, 
most commonly PA, a condition in which intrinsic factor production 
fails. There are many other causes of defective cobalamin absorption, 
involving the stomach, pancreas, or small intestine.  
Gastrectomy Syndromes: Gastric surgery often leads to anemia 
.Most common is iron-deficiency anemia, but cobalamin deficiency 
with megaloblastic anemia may also occur. After total gastrectomy, 
cobalamin deficiency will develop within 5 or 6 years because the 
 operation removes the source of intrinsic factor. The delay between 
surgery and the onset of cobalamin deficiency reflects the time needed 
to exhaust cobalamin stores after cobalamin absorption ceases.  
Postgastrectomy folate deficiency   from malabsorption or 
reduced dietary intake actually accounts for more cases of 
postgastrectomy megaloblastic anemia than does cobalamin 
deficiency. Often the two deficiencies occur together.   
Intestinal Disorders (Intestinal Diseases): 
 A number of intestinal disorders can lead to a deficiency of 
cobalamin. These include (1) extensive resection of the ileum,(36) (2) 
regional ileitis(37) or another disease affecting the ileum (e.g. 
lymphoma, radiation damage,(38) (3) cobalamin malabsorption 
associated with hypothyroidism(39) or certain drugs (4) the effects of 
cobalamin deficiency itself, and (5) sprue, either tropical or, less often, 
nontropical. In each of these, exogenous intrinsic factor fails to correct 
an abnormal Schilling test.  
Another cause of cobalamin deficiency is infestation with the 
fish tapeworm, Diphyllobothrium latum  
1.9.2. Dietary cobalamin deficiency: 
Dietary cobalamin deficiency is very unusual. It occurs mainly 
in vegetarians who also avoid dairy products and eggs (vegans).  Low 
serum cobalamin levels occur in 50 to 60 percent of this group. Breast-
fed infants of vegan mothers may also develop cobalamin deficiency. 
 Cobalamin deficiency in vegans presents with mild megaloblastic 
anemia, glossitis, and neurologic disturbances. Cobalamin deficiency 
may occur in severe general malnutrition. A megaloblastic anemia not 
related to cobalamin deficiency may accompany kwashiorkor or 
marasmus. 
The clinical picture of cobalamin deficiency includes the 
nonspecific manifestations of megaloblastosis-anemia, weight loss. 
plus specific features caused by the lack of cobalamin, chiefly 
neurologic abnormalities. Because cobalamin reserves are large, years 
may pass between the cessation of cobalamin absorption and the 
appearance of deficiency symptoms. This interval is shortened in 
patients whose enterohepatic cobalamin cycle has been interrupted. 
1.9.3. Laboratory features:  
1.9.3.1. Serum cobalamin levels:  
Serum cobalamin is low in most but not all patients with 
cobalamin deficiency.(40) Cobalamin levels are normal, however, in 
cobalamin deficiency due to N20, TC-ll deficiency, and inborn errors 
of cobalamin metabolism (see below); levels also may be normal in 
cobalamin-deficient patients with high TC-l levels due to 
myeloproliferative diseases.(41) Conversely, serum cobalamin levels 
may low in the presence of normal tissue cobalamin in vegetarians in 
subjects taking megadoses of ascorbic acid, in pregnancy (25 per. 
cent), in the presence of TC-I deficiency,(22) and in megaloblastic 
 anemia due to folate deficiency (30%). Serum folate may higher than 
expected in cobalamin deficiency; patients deficient in both cobalamin 
and folate may show normal serum folate levels.  
1.9.3.2. Methylmalonic aciduria: 
Except when caused by an inborn error (see below), 
methylmalonic aciduria is a reliable indicator of cobalamin 
deficiency.(42) Normal subjects excrete only traces of methylmalonate 
(0 to 3.4 mg/day); in cobalamin deficiency, however, urine 
methylmalonate is usually elevated. Cobalamin therapy restores 
excretion to normal in a few days.  
1.9.3.3. Serum methylmalonic acid and homocysteine: 
Elevated serum methylmalonic acid and homocysteine levels 
are indicators of tissue cobalamin deficiency. Their levels are high in 
more than 90 percent of cobalamin-deficient patients and rise before 
the serum cobalamin falls to subnormal levels. Elevated serum 
methylmalonic acid and/or elevated homocysteine are probably the 
most reliable indicators of cobalamin deficiency in patients without a 
congenital disorder in their metabolism.  
Spinal fluid methylmalonic acid levels are markedly elevated 
in cobalamin deficiency. 
1.9.3.4. The schilling test: assays of cobalamin absorption and 
               intrinsic factor:  
 Therapy, course, and prognosis: 
Treatment consists of parenteral cyanocobalamin (vitamin B12) 
or hydroxocobalamin to replace daily losses and refill storage pools. 
Which normally contain 2 to 5 mg of cohalamin.(2)Toxicity is nil, but 
doses exceeding 1000µ  saturate the transcobalamins, and the excess is 
lost in the urine. 
A typical treatment schedule consists of 1000 µg cobalamin IM 
daily for 2 weeks, then weekly until the hematocrit is normal, and 
then monthly for life. For neurologic manifestations, 1000µg every 2 
weeks for 6 months is recommended, and higher doses are given for 
certain inherited disorders (e.g., TC-Il deficiency). Cobalamin should 
be given by mouth for dietary cobalamin deficiency and to patients 
(e.g. hemophiliac patients) who cannot take IM injections.  
Transfusion is occasionally required when the hematocrit is less 
than 15 percent or when the patient is debilitated, infected, or in heart 
failure. In such instances, packed cells should be given slowly to 
avoid pulmonary edema. Infections can impair the response to 
cobalamin and must be treated vigorously.  
Use of oral cobalamin: 
Much interest has recently been kindled in the possibility of 
treating cobalamin deficiency with oral cobalamin.Oral cobalamin can 
be used not only for the treatment of the dietary cobalamin deficiency 
that occurs in vegans and in patients with very severe general 
 malnutrition but also for the treatment of patients with PA, provided 
these patients are followed carefully. In patients lacking intrinsic 
factor. About 1 percent of an oral dose of the vitamin is forced across 
the intestinal epithelium by mass action. Therefore, 1000 to 2000 
p.g/day of oral cobalamin will supply most PA patients with their 
daily cobalamin requirement without the need for injections and their 
accompanying pain and expense.  
1.9.3.5. Megaloblastic anemia caused by drugs:  
Many drugs that cause megaloblastic anemia, aminopterin and 
methotrexate are almost identical in structure to folic acid. After 
entering cells via the folate carrier and acquiring a polyglutamate 
chain, they act as very powerful inhibitors of dihydrofolate reductase. 
By blocking the FH2—FH4 reaction and perhaps inhibiting other 
enzymes of folate metabolism, they effect the rapid withdrawal of 
folates from the 1-carbon fragment carrier pool, causing a fall in 
nucleotide (especially thymidine) biosynthesis that leads to a major 
derangement in DNA replication.(43)  
Toxic effects include necrotic mouth lesions; ulcerations of the 
esophagus, small intestine, and colon, with abdominal pain, vomiting, 
and diarrhea megaloblastic anemia; alopecia; and hyperpigmentation. 
The drug is excreted by the kidney, so effects and toxicity are 
prolonged and enhanced if renal function is impaired.  
 Toxicity caused by these folate antagonists is treated with 
folinic acid (N5-formyl FH4). Folate itself is useless because the 
blocked reductase cannot convert it to the active tetrahydro form  
folinic acid. However, is already in the tetrahydro form and is 
therefore effective despite the reductase blockade. The usual dose of 
folinic acid is 3 to 6 mg/day TM. Larger doses are given in 
chemotherapy protocols in which folinic acid is used to rescue 
patients deliberately treated with otherwise fatal doses of 
methotrexate. Folinic acid was used intrathecally in a patient in whom 
a large overdose of methotrexate was accidentally delivered into the 
subarachnoid space.(44) 
Zidovudine (azidothymidine, AZT) is used for HIV infections 
(AIDS) .Its principal toxic effect is severe megaloblastic anemia. 
Anemia or neutropenia produced by zidovudine may limit the use of 
this drug.(45) 
HIV infection itself suppresses hematopoiesis, leading to 
pancytopenia with myelodysplastic features. The blood film shows 
vacuolated monocytes. Megaloblastosis in HIV infection may be due 
to folate or cobalamin deficiency or to AZT or trimethoprim toxicity.  
Hydroxyurea is used at high doses to treat chronic myelogenous 
leukemia, polycythaemia vera, and essential thrombocythaemia, and 
at lower doses to treat psoriasis. It inhibits the conversion of 
ribonucleotides to deoxyribonucleotides. Marked megaloblastic 
changes are routinely found in the marrow within 1 to 2 days of 
 initiating hydroxyurea therapy. These changes are rapidly reversed 
after withdrawing the drug. Megaloblastosis due to nitrous oxide 
(N2O) is discussed under “Acute Megaloblastic Anemia.” Long-term 
use of omeprazole and presumably other H/K-ATP- as inhibitors is 
associated with reduced serum cobalamin levels, presumably because 
of the ability of these drugs to inhibit parietal cell function.(45)This is 
not a problem when these drugs are used for short intervals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 JUSTIFICATIONS 
  
• This is first study was done on these profiles in Sudan, no similar 
studies has been done before. 
• Chronic disease had many effects on the body and its metabolism, so 
it can affect folate level by different ways, directly by the process of 
inflammation, and indirectly by the drugs used for these diseases.  
 
 
 
 
 
 
 
 
 OBJECTIVES 
General Objectives: 
• To determine the level of folate & B12 in patients with tuberculosis 
& rheumatoid arthritis. 
• To measure the haematological parameters in these patients. 
 
Specific Objectives: 
1-To measure folate level. 
2-To measure B12 level. 
3- To do complet blood count (CBC). 
 
 
  
 
 
 
 
 
 
 
 
 2. METHODOLOGY 
  
2.1. Study design, area, and duration: 
This is a prospective case control hospital-based study, 
conducted at Police Teaching Hospital and Abu Anjja Chest Hospital, 
during the period April 2005 to October 2005. 
2.2. Study population: 
The study included out patients with a diagnosis of either 
rheumatoid arthritis (n= 20) or tuberculosis (n=. 20) plus 5 healthy 
adults as control.  
2.3. Inclusion criteria: 
• Tuberculosis patients who are smear positive, chest x-ray 
positive and mantaeux positive. 
• Rheumatoid arthritis patients who had rheumatoid factor 
positive, anti nuclear factor positive, and with X ray changes. 
• All of these patients are newly diagnosed patients, who did not 
receive any drugs.  
2.4. Exclusion criteria: 
Patients who received drugs (antifolate), or vitamins, and not 
positive to any previously mentioned tests.  
 2.5. Tools and methodology: 
2.5.1. Consent: 
Verbal & written consent was taken from administration of 
hospital, treating doctors and from the patients (Appendix 2). 
 
2.5.2. Questionnaire:   
A questionnaire (Appendix 1) was designed, containing data 
regarding the personal data, name, age, sex and residence of patient, 
origin .It also contains clinical information, laboratory & radiological 
investigations, and drugs history. 
The clinical examination was done by the attending doctor 
2.5.3. Study protocol: 
Forty five patients & five healthy controls were studied. The 
age of study subjects ranged between 18-70 years, and included both 
males and females. 
2.5.4. Methods of blood collection:  
Blood was collected from patients under aseptic conditions. 
Three mls of venous blood were taken by a disposable syringe in 
(E.D.T.A), for doing complete blood count (C.B.C). Three mls were 
taken in plane tubes, left to clot, serum was separated & stored at 20˚C 
 until the time of analysis.Lipaemic or haemolysed samples were 
excluded. The sera were used for B12 & folate assays.        
2.5.4.1. Quantitative measurement of serum folate and B12: 
Serum folate and B12 were done by an 
Electrochemiluminescent (ECL) process. The Roche Elecsys 2010      
Immunoassay System is fully automated, random access, software 
controlled system for immunoassay analysis (Appendix 3). 
 
 
 
(ECL) Assay Principle: 
Electrochemiluminescent (ECL) processes are known to occur 
with many molecules including compounds of ruthenium, osmium, 
rhenium or other elements. 
ECL is processes in which highly reactive species are 
generated from stable precursors on a surface of an electrode .These 
highly reactive species react with one another, producing light. 
The development of ECL /Origen immunoassays is based on 
the use of a ruthenium [II]-tris [bipyridyl][Ru[bpy]3]2+ complex and 
tripropylamine [TPA]. The final chemiluminescent product is formed 
during the detection step. 
 The chemiluminescent reactions that lead to the emission of 
light from the ruthenium complex are initiated electrically, rather than 
chemically. This is achieved by appling a voltage to the 
immunological complexes [including the ruthenium complex] that are 
attached to streptavidin-coated microparticles. The advantage of 
electrically initiating the chemiluminescent reaction is that the entire 
reaction can be precisely controlled. 
Serum folate: 
Competition principle: Total duration of assay 27 minutes.  
• 1st incubation: By incubating 30 µL of sample with folate 
pretreatment reagents 1 and 2, bound folate is released from 
endogenous folate binding proteins. 
• 2nd incubation: By incubation the pretreatment sample with the 
ruthenium labeled folate binding protein, a folate complex is 
formed, the amount of which is dependent upon the analyte 
concentration  in sample. 
• 3rd incubation: After addition of streptavidin-coated microparticles 
and folate labeled with biotin, the unbound sites of the ruthenium 
labeled folate binding protein become occupied, with formation of 
ruthenium labeled folate binding protein-folate biotin complex. 
The entire complex becomes bound to the solid phase via 
interaction of biotin and streptavidin. 
 The reaction mixture is aspirated into the measuring cell where 
the microparticles are magnetically captured onto the surface of the 
electrode.  Unbound substances are then removed with Procell. 
Apllication of a voltage to the electrode then induces 
chemiluminescent emission which is measured by a photomultiplier. 
Results are determined via a calibration curve which is 
instrument-specifically generated by 2-point calibration and a master 
curve provided via the reagent barcode. 
Vitamin B12 
Test principle: 
Competition principle: 
Elecsys Vitamin B12 employs a competitive test principle using 
intrinsic factor specific for vitamin B12. Vitamin B12 in the sample 
competes with the added vitamin B12 labeled with biotin for the 
binding sites on the ruthenium-labeled intrinsic factor complex. 
Tris (2, 2-bipyridyl) ruthenium (ll)-complex (Rufbpyjj). Total 
duration of assay: 27 minutes. 
• 1st incubation: By incubating the sample (15 uL) with the vitamin B12 
pretreatment 1 and pretreatment 2, bound vitamin B12 is released. 
• 2nd incubation: By incubating the pretreated sample with the 
ruthenium labeled intrinsic factor, a vitamin B12-binding protein 
 complex is formed, the amount of which is dependent upon the 
analyte concentration in the sample. 
• 3rd incubation: After addition of streptavidin-coated microparticles 
and vitamin B12 labeled with biotin, the still-vacant sites of the 
ruthenium labeled intrinsic factor become occupied, with formation 
of a ruthenium labeled intrinsic factor-vitamin B12 biotin complex. 
The entire complex becomes bound to the solid phase via interaction 
of biotin and streptavidin. 
The reaction mixture is aspirated into the measuring cell where 
the microparticles are magnetically captured onto the surface of the 
electrode. Unbound substances are then removed with ProCell. 
Application of a voltage to the electrode then induces 
chemiluminescent emission which is measured by a photomultiplier. 
Results are determined via a calibration curve which is 
instrument-specifically generated by 2-point calibration and a master 
curve provided via the reagent barcode. 
2.5.4.2. Red cell measurement: 
The Sysmex® KX-21 is an automatic multi-parameter blood 
cell counter/or in vitro diagnostic use in clinical laboratories. 
The KX-21 processes approximately 60 samples an hour and 
displays on the LCD screen the particle distribution curves ofWBC, 
 RBC, and platelets, along with data of 18 parameters, as the analysis 
results. 
1. Overview of instrument: 
The KX-21 performs speedy and accurate analysis of 18 
parameters in blood and detects the abnormal samples. To assure easy 
sorting of abnormal samples in the laboratory, the instrument 
displays abnormal analysis data with abnormal marks attached on the 
LCD screen. Thus displayed analysis data allows detecting those 
samples which are outside the tolerance and need further analysis and 
reconsideration. 
The KX-21 employs three detector blocks and two kinds of 
reagents for blood analysis. The WBC count is measured by the WBC 
detector block using the DC detection method. The RBC count and 
platelets are taken by the RBC detector block, also using the DC 
detection method. The HOB detector block measures the hemoglobin 
concentration using the non-cyanide hemoglobin method. 
2. Detection principle: 
This instrument performs blood cell count by DC detection 
method. 
2.1 DC Detection Method: 
Blood sample is aspirated, measured to a predetermined 
volume, diluted at the specified ratio, and then fed into each 
 transducer. The transducer chamber has a minute hole called the 
aperture. On both side of the aperture, there are the electrodes 
between which flows direct current. Blood cells suspended in the 
diluted sample pass through the aperture, causing direct current 
resistance to change between the electrodes. As direct current 
resistance changes, the blood cell size is detected as electric pulses. 
Blood cell count is calculated by counting the pulses, and a 
histogram of blood cell sizes is plotted by determining the pulse sizes. 
Also, analyzing a histogram makes it possible to obtain various 
analysis data. 
2.2 Non-Cyanide Hemoglobin Analysis Method 
To analyze hemoglobin by automated methods, the 
cyanmethemoglobin method or oxyhemoglobin method have so far 
been the main stream. Cyanmethemoglobin method was 
recommended as the international standard method in 1966 by ICSH 
(International Committee for Standardization in Haematology). This 
method, however, is so low in hemoglobin conversion rate that it 
cannot be said an appropriate method in the automated process in 
which multi-sample processing is the pre-condition. In addition, this 
method uses the reagent of cyanide compound which is a poisonous 
substance and requires waste processing; thus, it can hardly be called 
an environmentally favorable method. 
 At present, this method cannot be said suitable for a fully-
automated instrument which is required to handle a large amount of 
waste. 
The oxyhemoglobin method, on the other hand, is faster in 
hemoglobin conversion rate; in fact, blood hemoglobin is converted 
instantaneously into oxyhemoglobin. Also, it does contain poisonous 
substance as cyanmethemoglobin method, making the method 
suitable for automation. This method, however, is unable to convert 
methemoglobin into oxyhemoglobin. Consequently, when a great 
amount of methemoglobin is contained as in control blood, lower-
than-real values result, although usual human blood poses no 
problems. 
Non-cyanide hemoglobin analysis method utilizes the 
advantages of both of the above methods. Non-cyanide hemoglobin 
analysis method rapidly converts blood hemoglobin as the 
oxyhemoglobin method and contains no poisonous substance, making 
it suitable for automated method. 
Being capable of analyzing methemoglobin, this method can 
accurately analyze control blood ...etc. which contain methemoglobin 
(See appendix) 
 
 
  
 
  
 
 
 
 
 
 RESULTS 
 
The total number of the subjects in this study was 45, 40 of 
them were patients with chronic disease, and 5 apparently healthy age 
and sex matched control subjects. 
The results were compared with both reference values 
provided by manufacturer of the assay kits and with the results of the 
control subjects. 
Characteristics of the studied patients: 
3.1. Disease distribution: 
Among 40 studied patients 20 patients had TB& 20 patients 
had rheumatoid arthritis (Table 1, Fig. 1).  
 
3.2. Age and gender distribution:  
Among studied patients the ages ranged from 20-70 years. 24 
were between 20-40 years, 15 were between 40-60years & 1person was 
>70 years. Among patients there were 16 males and 24 females with a 
ratio of 4:6. In the group of rheumatoid arthritis there are 2 males & 18 
females with a ratio of 1:9, and in the tuberculosis group males: 
females14:6 in ratio 7:3. (Table 2, Fig. 2). 
 
 3.3. Distribution according to haemoglobin level: 
 Five male patients were anaemic (Hb level below 12g/dl) and 
4 female patients were anaemic (Hb level below 11g/dl), (Table 3b          
& c, Fig. 3a, b & c). 
3.4 Distribution according to haematocrit level: 
 Ten (25%) patients had a low haematocrit (below 35%HCT). 
(Table 4, Fig. 4). 
3.5 Distribution according to MCV level: 
Ten (25%) patients had an MCV less than 80fL (Table 5, Fig. 5). 
3.6. Distribution according to MCH level: 
Eighteen (45)% of the patients had a low MCH of less than 
27pg, and 5% (2)patients of more than 34pg (Table 6, Fig. 6). 
3.7. Distribution according to MCHC level: 
Nineteen 47.5% of the patients had a low MCHC of less than 
32g/dL and 12.5% (5) had an MCHC of more than 34.5g/dL (Table 7,         
Fig. 7). 
3.8. Distribution according to folatelevel: 
There were 10 patients (25%) with low level of serum folate 
(less than 7ng /ml) (Tables 8, Fig. 8). 
3.9. Distribution according to B12 level: 
 The serum B12 was within normal level in all patients (> 69 
pg/ml) (Tables 9, Fig. 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Group Disease
A B 
Total 
RA 20 0 20 
TB 0 20 20 
Total 20 20 40 
 
A=RA= Reuhmatoid arthritis 
B= TB= Tuberculosis 
 
 
A=RA 
 B= TB 
 
Table: 1&Fig. 1:  Disease distribution 
 
DIAGNOSIS 
R  AT.B. 
Count 
22 
20 
18 
16 
14 
12 
10 
GROUPS
A
B
 GENDER Group 
MALE FEMALE 
Total 
R.A 2 18 20 
T.B 14 6 20 
Total 16 24 40 
                    
GROUPS
BA
C
ou
nt
20
10
0
GENDER
MALE
FEMALE
 
A=RA 
B= TB 
MALE FEMALE 
2 18 
14 6 
16 24 
 
 
Table 2& Figure. 2 Distribution according to gender 
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Fig. 3a: Distribution according to haemoglobin level in all patients 
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Table 3b &Fig. 3b: Distribution according to haemoglobin level in 
male 
 
Hg level (g/dl) Male 
7—11 5 
11—16 11 
16 and above 0 
Total 16 
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Table 3c &Fig. 3c: Distribution according to haemoglobin level in 
female 
 
 
Hg level (g/dl) Female 
7—12 4 
11—16 20 
16 and above 0 
Total 24 
  
Group A B C 
Hct% 25-35 3 7 0 
35-45 15 10 5 
45-50 2 3 0 
Total 20 20 5 
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A=RA 
B= TB 
                    C = Control 
Table. 4a& Fig.4a: Haematocrit 
  
Level Male Female 
25-35 4 6 
35-45 9 16 
45 and more 3 2 
Total 16 24 
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Fig. 4 b&Table .4b: Haematocrit. 
 
 
 
  
Level A B C 
64-79.9 2 8 0 
80-99 18 12 5 
100 and more 0 0 0 
Total 20 20 5 
 
A=RA 
B= TB 
                     C = Control 
0
2
4
6
8
10
12
14
16
18
20
A B C
64-79.9
80-99
100 and more
total
 
Fig.5:  &Table.5:  MCV 
 
  
 
MCH level A B C 
18 - 27 7 11 1 
27 - 32 11 9 4 
33 - 36 2 0 0 
Total 20 20 5 
 
A=RA 
                                                  B= TB 
                                                              C = Control 
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Table. 6& Fig. 6:  MCH 
 MCHC level A B C 
26 – 32 12 7 1 
32 – 34 8 5 4 
34 – 37 0 8 0 
Total 20 20 5 
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A= RA 
B = TB 
        C = Control 
Figure.7& Table.7: MCHC 
 Level A B C 
< 7 ng /ml 5 5 0 
>7 ng /ml 15 15 5 
Total 20 20 5 
 
A=RA 
                                                  B= TB 
                                                              C = Control 
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Table. 8a&Fig. 8a: Folate 
 
 
 Level Male Female 
< 7ng /ml 5 5 
>7ng /ml 15 15 
Total 20 20 
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Table. 8b&Fig. 8b: Folate 
 
 
 
 
 
 
 Level A B C 
< 69 pg/ml 0 0 0 
> 69 pg/ml 20 20 5 
Total 20 20 5 
 
A=RA 
                                                  B= TB 
                                                               C = Control 
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Table. 9&Fig. 9: B12 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
DISSCUSION 
 
The study groups were from different areas of Sudan and 
different tribes but all of them were located during the research 
period in khartuom, and had an age range from 20-70 years.  
This study is a prospective study, which was done in 45 
persons in whom 40 are patients with chronic disease, 20 had 
rheumatoid arthritis, and 20 had tuberculosis 
Selection criteria were 
- Patients not on medication.  
- Diagnosed for the first time by history, clinical finding, X-
rays (chest, joints), laboratory tests. 
This study was the first study of it`s type to be done in Sudan, 
there were no similar studies done before.  
In this study about 60% of the patients were between 20-40 
years (24 persons) between 41-60 years were (15 persons) 37.5% & 
above 60 (one patient) 2.5%. 
The majority of the patients were females, 24 persons. The 
males were 16. The females predominated over males specialy in 
 rheumatoid arthritis group in which there were 18 females and 2 
males .This reflects the distribution of the disease which is known to 
affect females more than males. In the other group with tuberculosis 
there were just 6 females while there were 14 males. 
According to the hemoglobin level, 9 patients had low levels, 6 
in tuberculosis group and 3 with rheumatoid arthritis .This may be 
due to the disease pathogensis.  
Also the hematocrit level was low among 10 patients, 6 
patients were females, and 4 were males. 7 of them with tuberculosis 
and 3 with rheumatoid arthiritis. 
The MCV was low in 10 patients, 7males and 3 females, 2 of 
them were in the rheumatoid group, and 8 in the tuberculosis group. 
The MCH was low in 18 patients, 8 were males, and 10 were 
females. In the group of rheumatoid 7 were females and no males, in 
the group of tuberculosis 8 were males and 3 were females. 
Nineteenth patients had low MCHC, among them 12 in the 
rheumatoid group, and 7 were in tuberculosis group. 
The results of folate were low in 10 patients, equal in numbers 
among both groups and gender; 5persons in each. 
The red cell indices indicate that about 40% of MCV & 45.5% of 
MCHC were less than normal and 17%of Hg was low.Anaemia with 
low red cell indices is a feature of anaemia of chronic disease. 
 Superadded iron deficiency was not excluded in these patients. The 
others may be anemic but red cells indicies may be normal and could 
be masked by folate deficiency. 
The serum B12 shows normal value and, the serum folate was 
low in one patient and subnormal in 9 patients. 
The control group was within normal range in all their 
heamatological parameters. 
The iron deficiency in anaemia of chronic disease (ACD) was 
distinguished by Mean cell volume (MCV), mean cell haemoglobin 
(MCH), mean cell haemoglobin concentration (MCHC). These are 
 lower in both groups, but more pronounced in iron deficient patients. 
Folic acid, and especially vitamin B12 deficiency, masked iron 
deficiency by increasing the MCV and MCH. It was concluded that 
generally more than one type of anaemia is present simultaneously in 
anaemic patients of ACD. The diagnosis of each type may be masked 
by another. Studies on pathogenesis of the anaemia are difficult as 
deficiencies generally coexist with ACD. Disease activity and, 
possibly, other factors play roles in ACD pathogenesis. 
- Shortened red cell life span, moderately 20-30% (from 120 to 60-90 
days).   
- Relative bone marrow(erythropoiesis) failure. 
 - Cytokines released from inflammatory cells (TNF-α,  IL-1, IFN-γ) 
affects erythropoiesis by inhibiting the growth of  erythroid 
progenitors. 
-  Serum erythropoietin levels in patiens with ACD are normal when 
compared to healthy subjects but much lower than levels in non-
ACD anemic patients.1 
Abnormal iron metabolism: 
In ACD, activation of the reticuloendothelial system with 
increased iron retention and storage within it impaired release of iron 
from macrophages to circulating transferrin (impaired reutilization of  
iron). 
Reduced concentration of transferrin (decreased production, 
increased sequestration in the spleen and in the foci of inflammation, 
increased loss). 
• Thirty six patients with rheumatoid arthritis (RA) (25 with anemia) 
were studied to establish the role of iron, vitamin B12, and folic acid 
deficiency, erythropoietin responsiveness, and iron absorption in the 
diagnosis and pathogenesis of anaemia in RA.(7)Iron deficiency, 
assessed by stainable bone marrow iron content, occurred in 13/25 
(52%), vitamin B12 deficiency in 7/24 (29%), and folic acid deficiency 
in 5/24 (21%) of the anaemic patients. Only 8/25 (32%) had just one 
type of anaemia. The iron deficiency of anaemia of chronic disease 
(ACD) was distinguished by ferritin concentration, which was 
 higher in that group. Mean cell volume (MCV) and mean cell 
haemoglobin (MCH) were lower in both anaemic groups, but most 
pronounced in iron deficient patients. Folic acid, and especially 
vitamin B12 deficiency, masked iron deficiency by increasing the 
MCV and MCH. Iron absorption tended to be highest in iron 
deficiency and lowest in ACD, suggesting that decreased iron 
absorption is not a cause of ACD in RA(7). 
• . Homocystine is one aminoacid product in long chaine of the 
metabolism of folte and B12 in status of their dificincy, it will be 
increased in the serum of the patients. It a metabolite of the amino 
acid methionine, are about 20-fold the normal concentration—is 
associated with greatly increased risk for premature vascular 
disease, sometimes leading to strokes or heart attacks. 
 A study was done on homocystine level from here they find about 
same percentage of nr of the patients 27.5%, with iron deficiency 
anemia of chronic disease.(24)  
 
Red cell contain large amounts of folate activity precursors, and that 
plasma and serum contains equal amounts of enzymatic factors 
(plasma factorsa) capable of releasing folate activity from folate 
activity precursors .Other study byAwad Omer&Alastair Mowat 1968 
on the plasma factor activity may also explain the altered 
erythrocyte/plasma folate ratio of 72:1 in patients with rheumatoid 
arthritis compared with a normal ratio of 42:1. (47) 
 So from here we find that, the effect of chronic disease on the 
folate and iron metabolism was quite obvius.  
As we know the rheumatoid arthritis and pulmonary 
tuberculosis  can affect on folate metabolism through enzymatic 
activity factors, which will suppress folate metabolite inside the cell 
,and outside the cell(folate monoglutamate (serum) folate 
polyglutamate (RBC), serum homocystine ) ,which then stoping 
conguations and formation of tetrahydro folate FH4  
The ACD is extremely common. ACD is more common that 
any anemia syndrome other than blood loss with consequent iron 
deficiency. ACD is the most common cause of anemia in hospitalized 
patients. After patients with bleeding, hemolysis, or known 
hematologic malignancy were excluded, 52% of anemic patients met 
laboratory criteria for the anemia of chronic disorders. ACD is 
observed in 27% of outpatients with rheumatoid arthritis and in 58% 
of new admissions to hospital rheumatology units.(1) 
Anemia in rheumatoid arthiritis patients is most likely due to 
anemia of chronic disease, chronic inflammatory, autoimmune 
disease, malnutrition malabsorption or drugs related .Many theories 
or studies were done.   
Anemia is present in 63% of tuberculosis patients. There are 
several reports associating mycobacterial disease with anemia, and 
several mechanisms have been proposed: nutritional deficiency, 
 failure of iron utilization, malabsorption syndrome and marrow 
suppression. The association of autoimmune hemolytic anemia with 
tuberculosis, although extremely rare, is known for quite long. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCULSIONS  
 
• In this study about 40% of the patients had anemia of chronic 
disease or iron deficiency anemia according to their red cell indices 
(Hg, MCH, MCHC and MCV). 
• About 10 of the patients had low serum folate 5: 5, male: female. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RECOMMENDATIONS 
 
• A further study in chronic disease needs to be done with increased 
numbers of patients in different types of diseases. 
• For further study in chronic disease to be done with serum and red 
cell folate. 
• To give folic acid supplement for patients with chronic diseases & 
to see the effect of this on the Hg level.  
• To do iron profile to confirim iron deficiency in ACD. 
• To do homocystein level also, because had increase risk of 
thrombosis. 
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APPENDIX  
1- QUESTIONNAIRE 
NAME:                                          DATE: 
AGE:                                            OCCUPATION: 
RESIDENCE:                              ORIGINE: 
DIAGNOSED ON Rh CLINIC: 
Ant inuclearfactor Rehumatiod factor ES 
   
X-RAY Tuberculin test AAFB 
   
C.B.C 
Hb Hct MCV MCH MCHC RDW 
      
BLOOD FILM 
RBC TWBC Platelats 
   
SERUM FOLATE SERUM  B12  
   
  
 
 tnesnoC-2
 
  :اﻻﺳﻢ
 
  :اﻟﻌﻤﺮ
  :اﻟﺴﻜﻦ
  :اﻟﻌﻤﻞ
  :اﻻﻗﺮار ﺑﺎﻟﻤﻮاﻓﻘﻪ ﻻﺧﺬ ﻋﻴﻨﻪ
 
 
 
 
 
 
 
 
 اﻻﻣﻀﺎء او ﺑﺼﻤﻪ
  
 
 
 
 
 
3-Quantitative measurement of serum folate and B12: 
 
     Serum folate and B12 had been measured with 
Electrochemiluminescent (ECL) process .The Roche Elecsys 2010 
Immunoassay System is fully automated, random access, software 
controlled system for immunoassay analysis. 
Electrochemiluminescent (ECL) processes are known to occur 
with many molecules including compounds of ruthenium, osmium, 
rhenium or other elements. 
ECL is process in which highly reactive species are generated 
from stable precursors at surface of an electrode .These highly reactive 
species react with one another, producing light. 
The development of ECL /Origen immunoassays is based on 
the use of a ruthenium [II]-tris [bipyridyl][Ru[bpy]3]2+ complex and 
 tripropylamine [TPA]. The final chemiluminescent product is formed 
during the detection step. 
The chemiluminescent reactions that lead to the emission of 
light from the ruthenium complex are initiated electrically, rather than 
chemically. This is achieved by Appling a voltage to the 
immunological complexes [including the ruthenium complex] that are 
attached to streptavidin-coated microparticles. The advantage of 
electrically initiating the chemiluminescent reaction is the entire 
reaction can be precisely controlled. 
 
 
2- Test principle: Folate: 
Competition principle: Total duration of assay 27 minutes. 
• 1st incubation: By incubating 30 µL of sample with folate 
pretreatment reagents 1 and 2, bound folate is released from 
endogenous folate binding proteins. 
• 2nd incubation: By incubation the pretreatment sample with the 
ruthenium labeled folate binding protein, a folate complex is 
formed, the amount of which is dependent upon the analyte 
concentration in sample. 
• 3rd incubation: After addition of streptavidin-coated microparticles 
and folate labeled with biotin, the unbound sites of the ruthenium 
 labeled folate binding protein become occupied, with formation of 
ruthenium labeled folate binding protein-folate biotin complex. The 
entire complex becomes bound to the solid phase via interaction of 
biotin and streptavidin. 
The reaction mixture is aspirated into the measuring cell where 
the microparticles are magnetically captured onto the surface of the 
electrode.  Unbound substances are then removed with Procell. 
Apllication of a voltage to the electrode then induce 
chemiluminescent emission which is measure by photomultiplier. 
Results are determined via a calibration curve which is 
instrument-specifically generated by 2-point calibration and a master 
curve provided via the reagent barcode. 
 Reagents - working solutions: 
PT1    Pretreatment reagent 1 (white cap), 1 bottle, 4.0 mL: 
Monothioglycerol 53.3 g/L: pH 5.5. 
PT2    Pretreatment reagent 2 (gray cap), 1 bottle, 4.0 mL: 
Sodium hydroxide 37 g/L. 
M      Streptavidin-coated microparticles (transparent cap), 1 
bottle, 6.5 mL: Streptavidin-coated microparticles, 0.72 mg/mL, 
binding capacity: 
470 ng biotin/mg microparticles; preservative. 
 R1 Folate binding protein-Ru (bpy) (gray cap), 1 bottle, 10 mL: 
Ruthenium labeled folate binding protein 50 ug/L; stabilizer; human 
serum albumin; borate/phosphate/citrate buffer, pH 5.5; 
preservative.  
R2     Folate-biotin (black cap), 1 bottle, 8.0 mL: Biotinylated folate 
18 ug/L; biotin 120 pg/L; stabilizer; human serum albumin; borate 
buffer, pH 9.0; preservative. 
Precautions and warnings. 
For in vitro diagnostic use. 
Exercise the normal precautions required for handling all 
laboratory reagents. Disposal of all waste material should be in 
accordance with local guidelines. Safety data sheet available for 
professional user on request. All human material should be 
considered potentially infectious. 
Reagent handling 
The reagents in the kit have been assembled into a ready-for-
use unit that cannot be separated. 
All information required for correct operation is read in via the 
respective reagent barcodes. 
Storage and stability 
Store at 2-8°C. 
 Store the Elecsys Folate II reagent kit upright in order to 
ensure complete availability of the microparticles during automatic 
mixing prior to use. 
Stability: 
unopened at 2-8°C:                up to the stated expiration date 
after opening at 2-8°C:             12 weeks 
on Elecsys 2010:                         1 week 
Specimen collection and preparation:  
Serum collected using standard sampling tubes or tubes 
containing separating gel.Do not use plasma.Stable for 2 hours at 20-
25°C, 2 days at 2-8°C, 1 month at -20°C. 
Freeze only once. Protect from light.Store the samples at 2-8°C 
or freeze at -20°C if they cannot be measured immediately. 
Stability of serum obtained with separating tubes: 24 hours at 
2-8°C (note the data provided by the tube manufacturer).9 
The sample types listed were tested with a selection of sample 
collection tubes that were commercially available at the time of 
testing, i.e. not all available tubes of all manufacturers were tested. 
Sample collection systems from various manufacturers may contain 
differing materials which could affect. The test results in some cases. 
When processing samples in primary tubes (sample collection 
 systems), follow the instructions of the tube manufacturer. Centrifuge 
samples containing precipitates before performing the assay. Do not 
use heat-inactivated samples. 
Note: Hemolysis may significantly increase folate values due 
to high concentrations of folate in red blood cells. Therefore, 
hemolyzed samples are not suitable for use in this assay. Serum for 
folate determinations should be collected from fasting persons. Ensure 
the patients' samples, calibrators, and controls are at ambient 
temperature (20-25°C) before measurement. Because of possible 
evaporation effects, samples, calibrators, and controls on the analyzer 
should be measured within 2 hours. 
Calibration: 
Calibration must be performing once per reagent lot using 
fresh reagent. Renewed calibration is recommended as follow: 
. After 1 month when using the same reagent. 
. As required e.g. if the quality control findings are outside the 
specified limits    
Quality control: 
Using Elecsys PreciControl Universal 1and 2 
Calculation:  
 The analyzer automatically calculates the analyte 
concentration.  
Conversion factor                         nmol/Lx0.44=ng/mL 
                                                         ng/mLx2.27=nmol/L 
 
Limitation-interference: 
 The assay is not affected by icterus (bilirubin < 684µmol/L or  
<40mg/dL, lipemia<1500mg/dL and biotin <30ng/mL 
Measuring range:  
0.6000-20.00 ng/mL or 1.36-45.4nmol/L 
Dilution: 
The recommended dilution is 1:2 
Expected values: 
 Normal                              7.0—39.7nmol/L(3.1-17.5ng/mL) 
Borderline deficient          5.0-6.8nmol/L(2.2-3.0 ng/mL) 
Excessive                           >39.7 nmol/L(>17.5ng/mL) 
Precision:  
Reproducibility was determined using Elecsys reagent,pooled 
human sera, and controls,n=21 within- run precision. 
 Analytical sensitivity: 
 (lower detection limit) 0.6 ng/mL (1.36 nmol/L) 
(master calibrator, standerd1+2sd,within-run precision. n =21 
Analytical specificity 
          The following cross-reactivities were found: 
Aminopterin       2.7% 
Folinic acid        2.3% 
Amethopterin      2.3% 
 
 
 
3- Vitamine B12 
Summary 
Radioassays were first reported for vitamin B12 in 1961. All 
utilize. Co-cyanocobalamin radiolabeled tracers and intrinsic factor 
for binding vitamin B12. The various commercial assays differ in their 
free versus bound separation techniques and choice of specimen 
pretreatment. The presence of endogenous serum binding proteins for 
cyanocobalamin (transcobalamins including R-protein) and of 
immunoglobulins directed against intrinsic factor require that 
 specimens are either boiled or treated at an alkaline pH to release the 
vitamin B12 and destroy the binding proteins. In the late 1970's, 
radioassays using serum binding proteins or partially purified 
intrinsic factor measured levels of vitamin B12 which exceeded those 
determined by microbiological methods. This was caused by trie 
presence of the serum binding protein or R-proteins in the assay. R-
protein specificity is poor compared to that of intrinsic factor and 
vitamin 812 analogs were being measured in addition to vitamin 812 
itself. Since that time, recommendations have been established for the 
use of highly purified intrinsic factor throughout the industry. 
Elecsys Vitamin B12 employs a competitive test principle using 
intrinsic factor specific for vitamin 812. Vitamin 812 in the sample 
competes with the added vitamin 812 labeled with biotin for the 
binding sites on the ruthenium-labeled intrinsic factor complexs. 
a) Tris (2,2'-bipyridyl)ruthenium(ll)-complex (Rufbpyjj^ Test principle 
Competition principle. Total duration of assay: 27 minutes. 
• 1st incubation: By incubating the sample (15 uL) with the vitamin 
B12 pretreatment 1 and pretreatment 2, bound vitamin B12 is 
released. 
• 2nd incubation: By incubating the pretreated sample with the  
ruthenium labeled intrinsic factor, a vitamin B12-binding protein 
complex is formed, the amount of which is dependent upon the 
analyte concentration in the sample. 
 •3rd incubation: After addition of streptavidin-coated microparticles 
and vitamin B12 labeled with biotin, the still-vacant sites of the 
ruthenium labeled intrinsic factor become occupied, with 
formation of a ruthenium labeled intrinsic factor-vitamin B12 biotin 
complex. The entire complex becomes bound to the solid phase via 
interaction of biotin and streptavidin. 
•   The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the 
electrode. Unbound substances are then removed with ProCell. 
Application of a voltage to the electrode then induces 
chemiluminescent emission which is measured by a 
photomultiplier. 
• Results are determined via a calibration curve which is instrument-
specifically generated by 2-point calibration and a master curve 
provided via the reagent barcode. 
 
 
 
Reagents working solutions     
Elecsys'Vitamin B12 reagent kit, Gat; Nd.'11820753322–l00 tests   
• PT1    Pretreatment reagent 1 (white cap); 1'bottle, 4 mL  
               Dithiothreitol 1.028 g/L; stabilizer, pH 5.5.    
• PT2    Pretreatment reagent 2 (gray cap), 1 bottle, 4 mil:  Sodium  
              hydroxide 40 g/L; sodium cyanide 2.205 ''g/L. 
• M      Streptavidin-coated microparticles (transparent cap); 1 bottle,  
             6.5 mL Streptavidin-coated microparticles, 0.72 mg/mL;  
Binding capacity 
470 ng biotin/mg microparticles; preservative.      
R1     Intrinsic factor-Ru^py^ (gray cap), 1 bottle/ 10 rriL:   
          Ruthenium, labeled .porcine.intrinsic,factor 4 ug/L; cobinamide; 
dicyanide 15 ug/L; stabilizer; human serum albumin; phosphate 
buffer, pH 5.5;: preservative.      
R2     Vitamin B12~biotin (black cap),, 1 bottle, 8.5 mL:   
          Biotinylated vitamin B12 25 ug/L; biotin 3 ug/L; phosphate 
          buffer, pH 7.0; preservative,  
Precautions and warnings: 
For in vitro diagnostic use. Exercise the normal precautions 
required for handling all. laboratory reagents., Disposal of all waste 
material should be in accordance with local guidelines. 
Safety data sheet available for professional user on request. 
 This kit contains components classified as follows according to 
the European directive.  
PT2: C-CORROSIVE, (sodium hydroxide) Causes burns. In case of 
contact with eyes, rinse immediately with plenty of water and 
seek medical advice. Wear suitable protective gloves and 
eye/face protection. 
PT2: Xn-HARMFUL,(sodium cyanide) Harmful by inhalation, in 
contact with skin and if .swallowed. Xn In case of accident or if 
you feel unwell, seek medical advice immediately (show the 
label where possible).      
All human material should be considered potentially 
infectious. All products derived from blood are prepared exclusively 
from the blood of donors tested individually and shown by FDA-
approved methods to be free from H8sAg and antibodies to HCV and 
HIV. However, as no testing method can rule out the potential risk of 
infection with absolute certainty, the material should be treated just as 
carefully as a patient specimen. In the event of exposure the directives 
of the responsible health authorities should be followed.9110   
Reagent handling                                       
The reagents in the kit have been assembled into a ready-for-
use unit that cannot be separated.                      
 All information required for correct operation is read in via the  
respective reagent barcodes.                 
 
 
 
 
Storage and stability                                    
Store at 2-8°C  
Store the Elecsys Vitamin 812 reagent kit upright, order to 
ensure complete availability of the microparticles during automatic 
mixing prior to use     
Stability:                                     
up to the stated expiration date 
unopened at 2-8°C: 
after opening at 2-8°C: 
on Elecsys 2010: . 
12 weeks 
5 weeks 
5 weeks      
 Specimen collection and preparation 
Only the specimens listed below were tested and found 
acceptable. Serum collected using standard sampling tubes or tubes 
containing separating gel.         
Na-heparin and Ks-EDTA plasma. When sodium citrate, 
fluoride/potassium oxalate are used, the values obtained' are by 23% 
lower as compared to serum.  
Criterion: 
Stable for 2 days at 2-8°C, 2 months at -20°C. Freeze once only. 
Protect from light.         
Stability of serum obtained with separating tubes: 24 hours at 
2-8°C (note the data provided by the tube manufacturer).  
When processing samples; in primary tubes, follow the 
instructions of the tube manufacturer. 
Centrifuge samples containing precipitates before performing 
the, assay. Do not use heat-inactivated samples. Do not use 
samplesand controls stabilized with azide. 
Vitamin 812 determinations should be performed on serum or 
plasma samples from fasting patients. 
Ensure the patients' samples, calibrators, and controls are at 
ambient temperature (20-25°C) before measurement. Because of 
 possible evaporation effects, samples, calibrators, and controls on the 
analyzers should be measured within 2 hours. 
Materials provided See "Reagents — working solutions" 
section for reagents. Materials required (but not provided).  
• Cat. No. 11820869322, Elecsys Vitamin Big CalSet, 4 x 1 mL 
• Cat. No. 11731416122, Elecsys PreciControl Universal, for 2 x 3 mL 
each of PreciControl Universal 1 and 2 
• Cat, No. 11732277122, Elecsys Diluent Universal, 2 x 18 mL sample 
diluent or Cat. No. 03183971122, Elecsys Diluent Universal, 2 x 40 
mL sample diluent 
• General laboratory equipment 
• Elecsys 2010 or MODULAR ANALYTICS E170 analyzer Accessories 
for Elecsys 2010: 
• Cat. No. 11662988122, Elecsys ProCell, 6 x 380 mL system buffer 
• Cat. No. 11662970122, Elecsys CleanCell, 6 x 380 mL measuring cell 
cleaning solution 
• Cat. No. 11930346122,'Elecsys SysWash, 1 x 500 mL washwater 
additive  
• Cat. No. 11933159001, Adapter for SysClean 
• Cat. No. 11706802001, Elecsys 2010 Assay Cup, 60 x 60 reaction 
 vessels 
•  Cat. No. 11706799001, Elecsys 2010 Assay Tip, 30 x 120 pipette tips  
 
Accessories for MODULAR ANALYTICS E170: 
•  Cat. No. 12135019190, ProCell M, 1 x 2 L system buffer   
•  Cat. No. 12135027190, CleanCell M, 1 x 2 L measuring cell cleaning 
solution 
•  Cat. No. 03023141001, PC/CC-Cups, 50 cups to prewarm ProCell 
M and CleanCell M before use 
•  Cat. No. 03005712190, ProbeWash M, 12 x 70 mL cleaning solution 
for run finalization and rinsing during reagent change 
•  Cat. No. 03004899190, PreClean M, 5 x 600 mL detection cleaning 
solution 
•  Cat. No. 12102137001, AssayCups/AssayTips Combimagazine M, 
48 magazines x 84 reaction vessels or pipette tips, waste bags 
•  Cat. No. 03023150001, WasteLiner, waste bags 
•  Cat. No. 03027651001, SysClean Adapter M  
 
 
  
 
Accessories for all analyzers: 
• Cat. No. 11298500316, Elecsys SysClean, 5 x 100 mL system cleaning 
solution Only available in the USA: 
•Cat. No. 11832778018, Elecsys Vitamin 812 CalCheck, 3 concentration 
ranges 
 Assay: 
For optimal performance of the assay, follow the directions 
given in this document for the analyzer concerned. Refer to the 
appropriate operator's manual for analyzer-specific assay instructions. 
Resuspension of the microparticles takes place automatically before 
use. Read in the test-specific parameters via the reagent barcode. If in 
exceptional cases the barcode cannot be read, enter the 15-digit 
sequence of numbers. 
E170/Elecsys 2010: Bring the cooled reagent to approx. 20°C 
and place on the reagent disk (20°C) of the analyzer. Avoid the 
formation of foam. The system automatically regulates the 
temperature of the reagents and the opening/closing of the bottles. 
Calibration: 
 Traceability: This method has been standardized against a 
commercially available radiobinding vitamin B12 assay. Every 
vitamin B12 reagent set has a barecoded label containing the specific 
information for calibration of the particular reagent lot. The 
predefined master curve is adapted to the analyzer by the use of 
Elecsys Vitamin B12 CalSet. 
Calibration frequency: Calibration must be performed once 
per reagent lot using fresh reagent (i.e. not more than 24 hours since 
the reagent kit was registered on the analyzer). Renewed calibration is 
recommended as follows: 
E170/Elecsys 2010:                       
• After 1 month (28 days) when using the same reagent lot. 
• After 7 days (when using the same reagent kit on the analyzer). 
• As required: e.g. if quality control findings are outside the specified 
limits.  
Calibration verification: Not necessary. The analyzer's 
software automatically checks the validity of the curve and draws 
attention to any deviations. 
Quality control: 
For quality control, use Elecsys PreciControl Universal 1 and 2. 
Other suitable control material can be used in addition. Controls for 
the various concentration ranges should be run as single 
 determinations at least once every 24 hours when the test is in use, 
once per reagent kit, and after every calibration. The control intervals 
and limits should be adapted to each laboratory's individual 
requirements. 
Values obtained should fall within the defined limits. Each 
laboratory should establish corrective measures to be taken if values 
fall outside the limits. 
 
 
Calculation 
The analyzer automatically calculates the analyte 
concentration of each sample (either in pmol/L or pg/mL). 
Conversion factors:      pmol/L x 1.36   = pg/mL 
                                          pg/mL x 0.738 = pmol/L 
Limitations • interference11 
The assay is unaffected by icterus (bilirubin < 1112 umol/L or 
< 65 mg/dL), hemolysis (Hb < 0.621 mmol/L or < 1.0 g/dL), lipemia 
(triglycerides < 17.1 mmol/L or < 1500 mg/dL), and biotin < 205 
nmol/L or < 50 ng/mL 
Criterion: Recovery within ± 10% of initial value. 
 In patients receiving therapy with high biotin doses (i.e. > 5 
mg/day), no sample should be taken until at least 8 hours after the 
last biotin administration. 
No interference was observed from rheumatoid factors up to a 
concentration of 1500 ILJ/mL. 
In vitro tests were performed on 54 commonly used 
pharmaceuticals. 
No interference with the assay was found. 
In rare cases, interference due to extremely high liters of 
antibodies to streptavidin and ruthenium can occur. 
For diagnostic purposes, the results should always be assessed 
in conjunction with the patient's medical history, clinical examination 
and other findings. 
 
Measuring ranger: 
22-1476 pmol/L or 30-2000 pg/mL (defined by the lower 
detection limit and the maximum of the master curve). Values below 
the detection limit are reported as < 22 pmol/L or < 30 pg/mL. Values 
above the measuring range are reported as > 1476 pmol/L or > 2000 
pg/mL  
Dilution: 
 Samples with vitamin B12 concentrations above the measuring 
range can be manually diluted 1:2 with Elecsys Diluent Universal. The 
concentration of the diluted sample must be > 738 pmol/L or > 1000 
pg/mL. After manual dilution, multiply the results by the dilution 
factor 2.  
Note: Sample-dependent non-linearity upon dilution is seen with 
samples 
Having analyte levels beyond the measuring range. As Elecsys 
Diluent Universal may contain low levels of endogenous vitamin B12, 
it is recommended that linearity studies be performed using a known 
low analyte-containing serum pool. Samples outside the measuring 
range can be diluted 1:2 with Elecsys Diluent Universal; the effect of 
endogenous vitamin B12 concentration is insignificant at these levels. 
 Vitamin B12 Expected values  
Because differences may exist with respect to population and 
dietary status, it is recommended that normal ranges be determined 
by each laboratory over a suitable period of time and in a statistically 
significant number of assays before clinical significance is attached to 
the results of these tests. The values shown below should only be used 
as a guideline. 
Results of a study in the USA and in the Netherlands 
Region N Range (2.5-97.5'" percentile) pmol/L pg/mL 
 Each laboratory should investigate the transferability of the 
expected values to its own patient population and if necessary 
determine its own reference ranges. 
Specific performance data11 
Representative performance data on the analyzers are given 
below. Results obtained in individual laboratories may differ. 
Precision: 
Reproducibility was determined using Elecsys reagents, 
pooled human sera, and controls in a modified protocol (EP5-A) of the 
NCCLS (National Committee for Clinical Laboratory Standards):12 6 
times daily for 10 days (n = 60); within-run precision  
Analytical sensitivity: 
 (Lower detection limit)    22 pgmol/L or 30 pg/mL 
The detection limit represents the lowest measurable analyte 
level that can be distinguished from zero. It is calculated as the value 
lying two standard deviations above that of the lowest standard 
(master calibrator, standard 1 + 2 SD, within-run precision, n = 21) 
 
 
 
 
 4- Measurement of red cell count 
 
The Sysmex® KX-21 is an automatic multi-parameter blood 
cell counter/or in vitro diagnostic use in clinical laboratories. 
The KX-21 processes approximately 60 samples an hour and 
displays on the LCD screen the particle distribution curves ofWBC, 
RBC, and platelets, along with data of 18 parameters, as the analysis 
results. 
 
Overview of Instrument: 
The important functions of the KX-21 and the options for 
efficient operation are explained. 
Main Points of Analysis Procedure 
Explanation is given on the procedure for implementing each 
analysis mode, descriptions and functions of the keys on panel 
keyboard, and the messages on the LCD screen. 
Precautions at Time of Installation: 
Explanation is given on the matters that need to be confirmed 
before installation, such as installation space, required equipment, 
environmental conditions. 
Instrument Specifications: 
 The instrument specifications are described. 
 
 
 
Menu Tree: 
This chapter describes the KX-21 menu tree and the 
corresponding chapters which explain the usage of the menus. 
2. Overview of instrument 
The KX-21 performs speedy and accurate analysis of 18 
parameters in blood and detects the abnormal samples. To assure easy 
sorting of abnormal samples in the laboratory, the instrument 
displays abnormal analysis data with abnormal marks attached on the 
LCD screen. Thus displayed analysis data allows detecting those 
samples which are outside the tolerance and need further analysis and 
reconsideration. 
The KX-21 employs three detector blocks and two kinds of 
reagents for blood analysis. The WBC count is measured by the WBC 
detector block using the DC detection method. The RBC count and 
platelets are taken by the RBC detector block, also using the DC 
detection method. The HOB detector block measures the hemoglobin 
concentration using the non-cyanide hemoglobin method. 
  
 
Figure 1-2-1: Overview of KX-21 
 
 
2. Detection principle: 
This instrument performs blood cell count by DC detection 
method. 
2.1 DC Detection Method: 
 Blood sample is aspirated, measured to a predetermined 
volume, diluted at the specified ratio, then fed into each transducer. 
The transducer chamber has a minute hole called the aperture. On 
both side of the aperture, there are the electrodes between which 
flows direct current. Blood cells suspended in the diluted sample pass 
through the aperture, causing direct current resistance to change 
between the electrodes. As direct current resistance changes, the 
blood cell size is detected as electric pulses. 
Blood cell count is calculated by counting the pulses, and a 
histogram of blood cell sizes is plotted by determining the pulse sizes. 
Also, analyzing a histogram makes it possible to obtain various 
analysis data. 
 
Figure 9-2-1: DC Detection Method 
 
2.2 Non-Cyanide Hemoglobin Analysis Method 
 To analyze hemoglobin by automated methods, the 
cyanmethemoglobin method or oxyhemoglobin method have so far 
been the main stream. Cyanmethemoglobin method was 
recommended as the international standard method in 1966 by ICSH 
(International Committee for Standardization in Haematology). This 
method, however, is so low in hemoglobin conversion rate that it 
cannot be said an appropriate method in the automated process in 
which multi-sample processing is the pre-condition. In addition, this 
method uses the reagent of cyanide compound which is a poisonous 
substance and requires waste processing; thus, it can hardly be called 
an environmentally favorable method. 
At present, this method cannot be said suitable for a fully-
automated instrument which is required to handle a large amount of 
waste. 
The oxyhemoglobin method, on the other hand, is faster in 
hemoglobin conversion rate; in fact, blood hemoglobin is converted 
instantaneously into oxyhemoglobin. Also, it does contain poisonous 
substance as cyanmethemoglobin method, making the method 
suitable for automation. This method, however, is unable to convert 
methemoglobin into oxyhemoglobin. Consequently, when a great 
amount of methemoglobin is contained as in control blood, lower-
than-real values result, although usual human blood poses no 
problems. 
 Non-cyanide hemoglobin analysis method utilizes the 
advantages of both of the above methods. Non-cyanide hemoglobin 
analysis method rapidly converts blood hemoglobin as the  
Oxyhemoglobin method and contains no poisonous substance, 
making it suitable for  automated method. 
Being capable of analyzing methemoglobin, this method can 
accurately analyze control blood,..etc. which contain methemoglobin. 
 
 
3. Measuring unit hydraulic system block diagram:  
  
 
Hydraulic system in whole blood and pre-diluted mode  
 
 
 
 
  
4. CBC ANALYSIS 
4.1 WBC/HGB Analysis Flow 
In WBC and HGB analysis, the volume of WBC and 
hemoglobin in the blood are measured. The flow of WBC/HGB 
analysis is described below: 
 
 
WBC/HGB Analysis Flow 
 
 Whole Blood Mode 
(1) Blood is aspirated from the sample probe into the sample rotor 
valve. 
 (2)  6 µL of blood measured by the sample rotor valve is 
transferred to the WBC transducer chamber along with 1.994 
mL of diluent. At the same time, 1.0 mL of WBC/HGB lyse is 
added to prepare 1:500 dilution sample. When the solution is 
made to react in this status for approximately 10 seconds, RBC 
is hemolyzed and platelets shrink, .with WBC membrane held 
as they are. At the same time, hemoglobin is converted into red 
colored methemoglobin. 
(3)  Of the diluted/hemolyzed sample in the WBC transducer  
chamber, approximately 1 mL is transferred to the HGB flow cell. 
(4)  500 (lL of sample in the WBC transducer is aspirated through the 
aperture. The pulses of the blood cells when passing through the 
aperture are counted by the DC detection method. 
(5)  In the HGB flow cell, 555 nm wavelength beam irradiated from 
the light emitting diode (LED) is applied to the sample in the 
HGB flow cell. Concentration of this sample is measured as 
absorbance. This absorbance is compared with that of the diluent 
alone that was measured before addition of the sample, thereby 
calculating HGB (hemoglobin value). 
• Pre-diluted Mode 
(1)  Blood sample that was diluted beforehand to 1:26 dilution using 
CELLPACK. This sample is aspirated from the sample probe into 
the sample rotor valve. 
 (2)  78 µL of diluted blood measured by the sample rotor valve is 
transferred to the WBC transducer chamber along with 1.922 mL 
of diluent. At this time, 1.0 mL of WBC/HGB lyse is added to 
prepare 1:1000 dilution sample. When the solution is made to 
react in this status for approximately 10 seconds, RBC is 
hemolyzed and platelets shrink, with WBC membrane held as 
they are. At the same time, hemoglobin is converted into red 
colored methemoglobin. 
(3)  Of the diluted/hemolyzed sample in the WBC transducer 
chamber, approximately 1 mL is transferred to the HGB flow cell. 
(4)  500 µL of sample in the WBC transducer chamber is aspirated 
through the aperture. The pulses of the blood cells when passing 
through the aperture are counted by the DC detection method. 
(5)  In the HGB flow cell, 555 nm wavelength beam irradiated from 
the light emitting diode (LED) is applied to the sample in the 
HGB flow cell. Concentration of this sample is measured as 
absorbance. This absorbance is compared with that of the diluent 
alone that was measured before addition of the sample, thereby 
calculating HGB (hemoglobin value). 
 
 
 
  
 
 
 
 
 
 
 
 
 
4.2 RBC7PLT Analysis Flow: 
In RBC/PLT analysis, RBC and platelet count in the blood are 
measured. The flow of RBC/PLT analysis is described below: 
  
Figure **: RBC/PLT analysis flow in whole blood mode 
 
(1) Blood is aspirated from the sample probe into the sample rotor 
valve. 
(2)  4.0 µL of blood measured by the sample rotor valve is diluted into 
1:500 with 1.996 mL of diluent and brought to the mixing chamber 
as diluted sample. (1st step dilution). 
(3)  Out of the 1:500 dilution sample, 40 pL is measured by the sample 
rotor valve, diluted into 1:25000 with 1.960 mL of diluent, then 
transferred to the RBC/PLT transducer chamber. (2nd step 
dilution). 
 (4)  250 µL of the sample in the RBC/PLT transducer chamber is 
aspirated through the aperture. At this time, RBC and PLT are 
counted by the DC detection method. At the same time, HCT 
(hematocrit value) is calculated by RBC pulse height detection 
method. 
 
RBC/PLT analysis flow in pre-diluted mode 
 
 (1)  Blood sample that was diluted beforehand to 1:26 dilution using 
CELLPACK. This sample is aspirated from the sample probe into 
the sample rotor valve. 
(2)  2.08 µL of diluted blood measured by the sample rotor valve is 
transferred in 1.99792 mL of diluent to the RBC/PLT transducer 
chamber, and is made into 1:25000 dilution sample. 
 (3)  Of the sample in the RBC/PLT transducer chamber, 250 (lL is 
aspirated through the aperture. At this time. RBC and PLT are 
calculated by the DC detection method. At the same time, HCT 
(hematocrit value) is calculated by RBC pulse height detection 
method. 
4.3 Calculation of RBC Constant 
RBC constant (mean RBC volume, mean RBC hemoglobin, 
mean RBC hemoglobin concentration) is calculated from RBC, HGB, 
and HCT. 
1.  Mean RBC Volume (MCV) 
Calculation is made from RBC and HCT by the formula below: 
                                               HCT (%) 
      MCV (fL) =                                            × 10 
                                           RBC (×106/µL) 
 
2.  Mean RBC Hemoglobin (MCH) 
 
  Calculation is made from RBC and HGB by the formula below: 
                                    HGB (g/dl) 
    MCH (pg) =                                        × 10 
                                 RBC (×106/µL) 
3.   Mean RBC Hemoglobin Concentration (MCHC) 
       Calculation is made from HCT and HGB by the formula below: 
                                          HGB (g/dl) 
    MCHC (g/dl) =                                        × 100 
                                              HCT (%) 
 
 
6.2 Analysis of RBC/PLT Histogram 
1. RBC Histogram: As mentioned earlier, RBC are determined as 
particle counts between two discriminators (LD) and (UD) which 
are automatically counted in the ranges of 25 – 75 fL and 200 - 250 
fL, respectively. As to histogram, check is made for relative 
frequency errors on respective discriminator levels, for more  
than one peak, and for distribution width error. In addition, this 
instrument is capable of expressing RBC distribution width 
(RDW) by two methods below: 
RDW-CV (RBC Distribution Width-Coefficient of Variation) is 
calculated by the formula below, after determining points LI and L2 
for 68.26% of the entire particle area: 
• Calculation of RDW-CV 
  
Figure *****: Calculation of RDW-CV 
RDW-SD (RBC Distribution Width - Standard Deviation) is set on 20% 
frequency level with the peak taken as 100%. 
• Definition of RDW-SD 
 
Definition of RDW-SD 
 
Instrument specifications: 
Analysis parameters: 
 WBC (White Blood cell Count), RBC (Red Blood cell Count), 
HGB (hemoglobin), HCT (hematocrit), MCV (mean corpuscular 
volume), MCH (mean corpuscular hemoglobin), MCHC (mean 
corpuscular hemoglobin concentration), PLT (platelet), RDW-SD (RBC 
distribution width-standard deviation), RDW-CV (RBC distribution 
width-coefficient of variation), PDW (platelet distribution width), 
MPV (mean platelet volume), P-LCR (platelet large cell ratio), LYM% 
(W-SCR), MXD% (W-MCR), NEUT% (W-LCR), LYM# (W- SCC), 
MXD# (W-MCC), NEUT# (W-LCC) (RDW-SD or RDW-CV: Switch 
over type) However, the parameters in pre-diluted mode are eight: 
WBC, RBC, HGB, HCT, MCV, MCH, MCHC. PLT. 
 
 
 
Display range 
WBC  0.0 - 299.9 (×103/µL) 
RBC    0.00 -19.99 (×106/µL) 
HGB   0 - 25.0 (g/dL) 
PLT    0 -1999 (×103/µL) 
 
Reagent 
 Diluent: CELLPACK 
WBC/HGB lyse reagent: STROMATOLYSER-WH 
 
Detergent 
CELLCLEAN 
Consumption of reagent (per sample) 
Diluent (CELLPACK): Approx. 30 mL. 
WBC/HGB lyse reagent (STROMATOLYSER-WH): Approx. 1.0 mL 
Throughput 
Approx. 60 samples/hour 
Analysis principle 
WBC: DC detection method 
RBC: DC detection method 
HGB: Non-cyanide hemoglobin analysis method. 
 
 
 
 
 Reproducibility 
Reproducibility is within the following range at the reliability level of 
95%. 
1)   Whole blood mode  
WBC (4.0 × 103/µL or over) 3.5% or less 
RBC (4.00 × 106/µL or over) 2.0% or less 
HGB 1.5% or less 
HCT 2.0% or less 
MCV 2.0% or less 
MCH 2.0% or less 
MCHC 2.0% or less 
PLT (100 × 103/µL or over) 6.0% or less 
LYM# (W-SCC) 15.0% or less 
MXD# (W-MCC) (1.0×103/µLor 
over) 
30.0% or less 
NEUT# (W-LCC) 15.0% or less 
LYM% (W-SCR) 15.0% or less 
MXD% (W-MCR)(12% or over) 30.0% or less 
 NEUT% (W-LCR) 15.0% or less 
RDW-SDorRDW-CV 4.0% or less 
PDW 12.0% or less 
MPV 5.0% or less 
P-LCR 20.0% or less 
 
2)   Pre-diluted mode: 
 
WBC (4.0 × 103/µL or over) 6.0%  or less 
RBC (4.00 × 106/µL or over) 3.0% or less 
HGB 2.5% or less 
HCT 3.0% or less 
MCV 3.0% or less 
MCH 3.0% or less 
MCHC 3.0% or less 
PLT (100 × 103/µL or over) 9.0% or less 
Accuracy  
1)   Whole blood mode  
 WBC: ±3% or ±0.2 × 103/µL or less 
RBC: ±2% or ±0.03 × 106/µL or less 
PLT: ±5% or ±10 × 103/µL or less 
2)   Pre-diluted mode  
WBC: ±5% or ±0.3 × 103/µL or less 
RBC: ±3% or ±0.05 × 106/µL or less 
PLT: ±8% or ±15 × 103/µL or less 
 
Linearity 
1)   Whole blood mode 
WBC:    1.0 -9.9 (× 103 /µL)   ±0.3 (× 103 /µL)  ) or less 
              10.0 – 99.9 (× 103 /µL)   ±3% or less 
RBC:   0.30 - 0.99 (× 106 /µL)   ±0.03 (× 106 /µL)  or less 
            1.00-7.00 (× 106 /µL)   ±3% or less 
HGB:   0.1-10.0 (g/dL) ±0.2 (g/dL) or less 
              10.0 – 25.0 (g/dL) ±2% or less 
HCT:   10.0 - 33.3 (HCT %) ±1.0 (HCT%) or less 
               33.4 - 60.0 (HCT %) ±3% or less 
PLT:    10 -199 (× 103 /µL)   ±10 (× 103 /µL) or less 
             200 - 999 (× 103 /µL)   ±5% or less 
    (However, RBC < 7.00 × 106 /µL)   
 
Blood volume aspirated 
Whole blood mode: Approx. 50 µL 
Pre-diluted mode:   Approx. 200 µL (Diluted blood sample) 
                                    Blood volume required for the pre-dilution is  
      20 µL or over. 
Power supply 
117/220/230/240 VAC ± 10% or less (50/60 Hz) 
Power consumption 
Approx. 230 VA or less 
Dimensions 
Main Unit: 420 (W) x 355 (D) x 480 (H) mm 
Weight 
Main Unit: Approx. 28.0 kg 
